




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/14, A61K 31/47, 31/55		A1	(11) International Publication Number: WO 96/33993
			(43) International Publication Date: 31 October 1996 (31.10.96)
(21) International Application Number: PCT/EP96/01459			(81) Designated States: AU, BR, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RU, SG, TR, US, VN, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 1 April 1996 (01.04.96)			
(30) Priority Data: 9508622.9 28 April 1995 (28.04.95) GB			Published With international search report.
(71) Applicant (for all designated States except GB JP US): PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. [BE/IE]; La Touche House, International Financial Services Centre, Dublin 1 (IE).			
(71) Applicant (for GB only): PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).			
(71) Applicant (for JP only): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).			
(72) Inventor; and			
(75) Inventor/Applicant (for US only): DANILEWICZ, John, Christopher [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).			
(74) Agents: MOORE, James, William et al.; Pfizer Limited, European Patent Dept., Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).			

(54) Title: ANTITHROMBOTIC AMIDINOTETRAHYDROPYRIDYLALANINE DERIVATIVES

(57) Abstract

Compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates of either entity, wherein Y is optionally monounsaturated C₃-C₅ alkylene optionally substituted with C₁-C₄ alkyl or methylene; R¹ is H; C₁-C₄ alkyl optionally substituted with C₁-C₄ alkoxy, OH, NR⁵R⁶, CONR⁵R⁶, C₃-C₆ cycloalkyl or aryl; or C₃-C₆ alkenyl; R² is H; C₁-C₄ alkyl optionally substituted with C₁-C₄ alkoxy, OH, NR⁵R⁶, CONR⁵R⁶, C₃-C₆ cycloalkyl or aryl; or CONR⁵R⁶; R³ and R⁴ are each independently selected from H; C₁-C₄ alkyl optionally substituted with NR⁵R⁶; C₁-C₄ alkoxy; halo; CONR⁵R⁶ and aryl; aryl is phenyl optionally substituted with one, two or three substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halo and CF₃; R⁵ and R⁶ are each independently selected from H and C₁-C₄ alkyl; and m and n are each independently 1, 2 or 3; are potent and selective thrombin inhibitors useful in the treatment of, *inter alia*, deep vein thrombosis; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; restenosis and occlusion following angioplasty; or neurodegenerative disorders.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

ANTITHROMBOTIC AMIDINOTETRAHYDROPYRIDYLALANINE
DERIVATIVES

5 This invention relates to a series of amidinotetrahydropyridylalanine derivatives, which are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisation trauma, application of lower limb plaster casts, or
10 fractures of the lower limbs or pelvis; recurrent DVT; DVT during pregnancy when there is a previous history thereof; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; disseminated intravascular coagulation;
15 coagulation in extra-corporeal circuits; occlusion of arterio-venous shunts and blood vessel grafts (including coronary artery by-pass grafts); and restenosis and occlusion following angioplasty. They also have utility as an adjunct to thrombolytic therapy.

 The compounds of the invention are potent and selective inhibitors of
20 thrombin, which is the final serine protease enzyme in the coagulation cascade. The prime function of thrombin is the cleavage of fibrinogen to produce fibrin which forms linear insoluble polymers which, in turn, are cross-linked by factor XIIIa, itself activated by thrombin. In addition, thrombin regulates its own production by activation of factors V and VIII earlier in the cascade. It also has
25 important actions at the cellular level, where it acts on specific receptors to cause platelet aggregation, endothelial cell activation and fibroblast proliferation. Thus thrombin has a central regulatory role in homeostasis and thrombus formation.

 Clearly then, potent, selective and orally bioavailable thrombin inhibitors
30 represent an attractive target for the convenient therapeutic control of thrombosis. In addition, thrombin potently causes neurite retraction and

-2-


therefore a thrombin inhibitor is of potential therapeutic utility in the treatment of acute and chronic neurodegenerative disorders. Furthermore, the

5 compounds disclosed herein are of potential value in the treatment of inflammatory disorders and scarring, and in wound healing.

Because of their potential as substrate mimics, arginine derivatives have been explored as thrombin inhibitors and this work led to the discovery of argatroban (see Cardiovascular Drug Rev., 1991, 9, 247). In turn, other
10 research groups have sought to express the basic arginine function in a variety of alternative structures; for example, WO-A-92/08709 discloses amidino, guanidino, amidoximino, aminomethyl and amino phenylalanine derivatives as antithrombotic agents.

The compounds of the present invention are significantly more potent
15 thrombin inhibitors than those mentioned above, selective (in comparison with their inhibition of, for example, trypsin, plasmin, butyrylcholinesterase and elastase), well tolerated and orally bioavailable.

Accordingly, the present invention provides a compound of formula (I):



-3-

pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates of either entity,

- 5 wherein Y is optionally monounsaturated C₃-C₅ alkylene optionally substituted with C₁-C₄ alkyl or methylene;
R¹ is H; C₁-C₄ alkyl optionally substituted with C₁-C₄ alkoxy, OH, NR⁵R⁶, CONR⁵R⁶, C₃-C₆ cycloalkyl or aryl; or C₃-C₆ alkenyl;
R² is H; C₁-C₄ alkyl optionally substituted with C₁-C₄ alkoxy, OH,
10 NR⁵R⁶, CONR⁵R⁶, C₃-C₆ cycloalkyl or aryl; or CONR⁵R⁶;
R³ and R⁴ are each independently selected from H; C₁-C₄ alkyl optionally substituted with NR⁵R⁶; C₁-C₄ alkoxy; halo; CONR⁵R⁶ and aryl;
R⁵ and R⁶ are each independently selected from H and C₁-C₄ alkyl;
15 and m and n are each independently 1, 2 or 3.

In the above definition, aryl means phenyl optionally substituted with one, two or three substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halo and CF₃; halo means fluoro, chloro, bromo or iodo. Unless otherwise
20 indicated, alkyl and alkoxy groups having three or more carbon atoms and alkenyl groups having four or more carbon atoms may be straight-chain or branched-chain.


The compounds of formula (I) contain two or more asymmetric centres and thus can exist as stereoisomers, i.e. as enantiomers or as
25 diastereoisomers, and the invention includes both the separated individual stereoisomers as well as mixtures thereof.

-4-

The preferred stereoisomers are of formula (IA):

5

10



Also included in the invention are radiolabelled derivatives of compounds of formula (I) which are suitable for biological studies.


The pharmaceutically acceptable salts of the compounds of formula (I) are, for example, non-toxic acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, sulphuric and phosphoric acid, with organo-carboxylic acids, or with organo-sulphonic acids. Compounds of formula (I) can also provide pharmaceutically acceptable metal salts, in particular non-toxic alkali metal salts, with bases. Examples include the sodium and potassium salts.

A preferred group of compounds of formula (I) is that wherein Y is optionally monounsaturated C_4 alkylene substituted with methyl or ethyl; R^1 is C_1 - C_4 alkyl; R^2 is H; R^3 and R^4 are H; and m and n are each independently 1 or 2.

A more preferred group of compounds is that of formula (IB):

5

10



15 wherein --- represents an optional carbon-carbon single bond; R^1 and R^7 are methyl; m is 1 or 2; and n is 2.

Particularly preferred individual compounds of the invention include:

4-methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid;

20 2(R)-carboxylic acid;

4-methyl-1-[N-(3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid; and


4(R)-methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-carboxylic acid;

25 (1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-carboxylic acid;

and pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates of either entity.

30 In another aspect, the present invention provides processes for the preparation of compounds of formula (I) and their pharmaceutically acceptable salts.


A compound of formula (I) may be prepared by hydrolysis of its lower alkyl ester precursor of formula (II):



wherein R^8 is C_1 - C_3 alkyl, preferably methyl or ethyl, and Y , R^1 , R^2 , R^3 , R^4 , m and n are as previously defined for formula (I). The reaction may be acid- or base-catalysed, but is generally carried out using an alkali metal hydroxide such as sodium or potassium hydroxide in aqueous solution, optionally in the presence of a suitable cosolvent, at from about $0^\circ C$ to about $100^\circ C$. Preferred conditions are the use of aqueous sodium hydroxide solution at from about $0^\circ C$ to about room temperature.

20 The novel intermediate esters of formula (II) also form part of the invention.


A compound of formula (II) may be prepared from a compound of formula (III):



-7-

wherein P is a conventional amine protecting group and Y, R¹, R², R³, R⁴, R⁸, m and n are as previously defined for formula (II). This may be achieved by
 5 double-deprotection of the protected amidine group under standard conditions.
 When P is the preferred protecting group, i.e. t-butoxycarbonyl (Eoc), deprotection may be effected under acidic conditions, e.g. using trifluoroacetic acid or hydrogen chloride in a suitable solvent. Preferably the reaction is
 10 conducted using hydrogen chloride in dichloromethane at from about 0°C to about room temperature.

A compound of formula (III) may be prepared by N-alkylation of a compound of formula (IV):



wherein P, Y, R², R³, R⁴, R⁸, m and n are as previously defined for formula (III),
 25 with the proviso that none of the other nucleophilic centres within (IV) provides a more reactive alkylation site, e.g. in certain cases where R², R³ or R⁴ is C₁-C₄ alkyl substituted with NR⁵R⁶.


In general, the alkylation may be achieved by reaction of a compound of formula (IV) with a compound of formula R¹Q, wherein R¹ is as previously
 30 defined for formula (III) and Q is a suitable leaving group, e.g. halo, C₁-C₄ alkanesulphonyloxy, trifluoromethanesulphonyloxy or arylsulphonyloxy (such as benzenesulphonyloxy or *p*-toluenesulphonyloxy), in the presence of an

-8-

appropriate base, e.g. the carbonate or bicarbonate salt of an alkali or alkaline earth metal, in a suitable solvent such as a C₁-C₃ alkanol, acetonitrile, dimethylformamide or N,N-dimethylacetamide, optionally in the presence of the iodide salt of sodium or potassium, at from about room temperature to about 100°C. Preferably Q is chloro, bromo or iodo, the base is sodium or potassium carbonate or bicarbonate, the solvent is acetonitrile and the reaction is conducted at about 80-85°C.

When R¹ is methyl, the N-methylation can be conveniently carried out by a reductive alkylation procedure wherein (IV) is treated with aqueous formaldehyde solution followed by an appropriate reducing agent in a suitable solvent. Preferably both reaction steps are conducted at room temperature in dichloromethane as solvent, with sodium triacetoxyborohydride being employed in the reduction step.


A compound of formula (IV) may be prepared by N-deprotection of a compound of formula (V):



wherein P¹ is a protecting group and P, Y, R², R³, R⁴, R⁸, m and n are as previously defined for formula (IV). P¹, which represents a conventional amine protecting group, is chosen with due regard to its compatibility with the various reagents employed in earlier synthetic steps of the over-all process and also to

the reaction conditions required for its selective removal; preferably, it is trifluoroacetyl. The particular protecting group can be removed under standard conditions which, in the case of trifluoroacetyl, are mild aqueous base optionally in the presence of a C₁-C₃ alkanol as cosolvent. Preferred conditions are sodium or potassium carbonate in aqueous methanol or ethanol at about room temperature.


A compound of formula (V) may be prepared from a compound of formula (VI):



20

wherein P¹, Y, R², R³, R⁴, R⁸, m and n are as previously defined for formula (V), by reaction with a S-alkylisothiurea derivative of formula (VII):

25




30 wherein R⁹ is C₁-C₃ alkyl and P is as previously defined for formula (V), in a suitable solvent, optionally in the presence of a mercury(II) salt, at from about 0°C to about room temperature.

A compound of formula (VI) may be prepared from a compound of formula (VIII):

5

10




wherein P^1 , Y , R^2 , R^3 , R^4 , R^8 , m and n are as previously defined for formula (VI),
 15 using a standard N-dealkylation reagent. In a preferred procedure, the debenzylation is effected by, in a first step, reaction of (VIII) with 1-chloroethyl chloroformate, optionally in the presence of 1,8-bis(dimethylamino)-naphthalene, in a suitable solvent such as dichloromethane, 1,2-dichloroethane or toluene, at from about 0°C to about 110°C , followed by a second step in
 20 which the intermediate carbamate is heated under reflux with a C_1 - C_3 alkanol. Preferably, in the first step the solvent is dichloromethane and the reaction temperature is at from about 0°C to about room temperature, while in the second step the alkanol is methanol or ethanol.


A compound of formula (VIII) may be assembled by a number of
 25 strategies. One approach may involve the coupling of a compound of formula (IX):

5

10



wherein P^1 , R^2 , R^3 , R^4 , m and n are as previously defined for formula (VIII), with
 15 a compound of formula (X):



20

wherein Y and R^8 are as previously defined for formula (VIII). The coupling reaction may be achieved using conventional amide bond-forming techniques. For example, the acid may be activated by formation of the corresponding acyl halide, e.g. bromide or chloride, followed by reaction of the latter with an amine of formula (X), optionally in the presence of a reaction-inert base to act as acid scavenger, in a suitable solvent such as dichloromethane. Alternatively, any of
 25 a host of peptide coupling variations may be used. For example, the acid may be activated using a carbodiimide such as 1,3-dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, optionally in the presence of 1-hydroxybenzotriazole and, where appropriate, a reaction-inert amine such as
 30 N-methylmorpholine or N-ethyldiisopropylamine (for example when either (X) or the carbodiimide is in the form of an acid addition salt) and/or a catalyst such


-12-

as 4-dimethylaminopyridine, in a suitable solvent such as dichloromethane.

Thus, in a preferred process, (IX) is converted to the corresponding acyl

5 chloride using oxalyl chloride and a catalytic amount of dimethylformamide in a suitable solvent, e.g. dichloromethane, at about 0-5°C and then the acyl chloride is reacted with (X), optionally as a suitable acid addition salt, in the presence of N-ethyldiisopropylamine as reaction-inert base in dichloromethane at from about 0°C to about room temperature.

10 A compound of formula (IX) may be prepared from a corresponding ester of formula (XI):



wherein R^{10} is $\text{C}_1\text{-C}_4$ alkyl or benzyl, and P^1 , R^2 , R^3 , R^4 , m and n are as previously defined for formula (IX). Preferably R^{10} is t-butyl.

25 The conversion of (XI) to (IX) can be effected by standard hydrolytic or O-dealkylation procedures and will be dependent on the nature of P^1 . For example, when R^{10} is t-butyl and P^1 is trifluoroacetyl, protonolysis using a reagent such as trifluoroacetic acid or hydrogen chloride in a suitable solvent is the method of choice. Preferably the reaction is conducted using hydrogen


30 chloride in dichloromethane at from about 0°C to about room temperature.

A compound of formula (XI) may be prepared by sulfonylation of a compound of formula (XII):

-13-


5

10



wherein R^{10} is as previously defined for formula (XI), optionally as a suitable
 15 acid addition salt, with a compound of formula (XIII):

20




25 wherein Z is halo, preferably chloro, and P^1 , R^2 , R^3 , R^4 , m and n are as previously defined for formula (XI), under conventional conditions in the presence of a reaction-inert base in a suitable solvent at from about 0°C to about room temperature. Preferably the base is N-ethyldiisopropylamine and the solvent is dichloromethane.

30 A compound of formula (XII) may be prepared by N-deprotection of a compound of formula (XIV):

-14-

5

10




15

wherein R^{10} is as previously defined for formula (XII) and P is as previously defined for formula (VII). As for a compound of formula (III), P is preferably Boc and (XIV) may be similarly deprotected. However, when R^{10} is the preferred group (t-butyl), the deprotection method of choice involves the use of neat formic acid at about room temperature.

20

A compound of formula (XIV) may be prepared by partial reduction of a compound of formula (XV):

25



30


-15-

wherein P and R¹⁰ are as previously defined for formula (XIV) and Z is as previously defined for formula (XIII) but is preferably bromo, using a
5 conventional reducing agent in a C₁-C₃ alkanol. A preferred method employs sodium borohydride in ethanol at about 0°C.

A compound of formula (XV) may be prepared by N-benylation of a compound of formula (XVI):

10

15



20


wherein P and R¹⁰ are as previously defined for formula (XV), using the appropriate benzyl halide in a suitable solvent under standard conditions, e.g. benzyl bromide in ethanol at about room temperature.

The N-protected α-amino ester of formula (XVI) is obtainable from the
25 corresponding α-amino acid, 3-(3-pyridyl)alanine (see Int. J. Pept. Prot. Res., 1987, 29, 118 for S- and R-enantiomers), using conventional amino acid protecting group chemistry. This may be achieved, for example, by effecting N-protection initially, followed by esterification of the carboxyl group using the appropriate alcohol of formula R¹⁰OH.

30

A compound of formula (XIII) may be prepared from a compound of formula (XVII):

5




10

wherein P^1 , R^2 , R^3 , R^4 , m and n are as previously defined for formula (XIII), by the application of known methods for the electrophilic introduction of a SO_2Z group, wherein Z is as previously defined for formula (XIII), into an aromatic ring system. For example, when Z is chloro, by the action of chlorosulphonic acid at from about $-15^\circ C$ to about room temperature.

A compound of formula (XVII) may be prepared from a compound of formula (XVIII):

20



25


wherein R^2 , R^3 , R^4 , m and n are as previously defined for formula (XVII), by conventional procedures. For example, when P^1 is trifluoroacetyl, by using trifluoroacetic anhydride, optionally in the presence of a base such as N-methylmorpholine or N-ethyldiisopropylamine and a solvent such as dichloromethane at from about $0^\circ C$ to about room temperature.

30

-17-

A compound of formula (X) may be prepared by a variety of methods, e.g. by standard cyclic α -amino acid/ester syntheses, and, when a particular stereoisomer is required, by classical resolution procedures or by asymmetric synthesis.

For example, when (X) represents a compound of formula (XA):





15

wherein R^7 is as previously defined for formula (IB) and R^8 is as previously defined for formula (X), 4-methylpyridine offers a convenient starting point and may be processed as follows. Following quarternisation by alkylation, e.g. using a conventional methylation procedure, the resulting pyridinium salt is subjected to partial reduction using sodium borohydride followed by *in situ* α -cyanation of the 2,5-dihydropyridine intermediate using hydrogen cyanide to afford, in this example, 1-methyl-2(R,S)-cyano-4-methyl-1,2,3,6-tetrahydropyridine. Next, the nitrile is converted to the required ester derivative and N-demethylation effected using a suitable chloroformate, e.g. 2,2,2-trichloroethyl chloroformate. Finally, N-deprotection is carried out using the appropriate reagent, e.g. zinc dust in this example.

An alternative approach to a compound of formula (XA) involves aza Diels-Alder cycloaddition chemistry in which an imine of formula (XIX), wherein P^2 is a suitable protecting group, e.g. benzyl, is reacted with a diene of formula (XX):

5



10

(see Tetrahedron:Asymmetry, 1991, 2, 1263), followed by N-debenzylation, again using a chloroformate reagent, e.g. 1-chloroethyl chloroformate in this case. The final N-deprotection may be achieved using excess alcohol (R^8OH) at about reflux temperature.

15 Clearly, reduction of (XA), e.g. by catalytic hydrogenation, will provide the corresponding piperidine-2-carboxylic esters.


When P^2 also acts as a chiral auxiliary, e.g. it is 1(R)- or 1(S)-phenylethyl, a useful degree of asymmetric induction is achievable in the (4+2) cycloaddition reaction affording a mixture of easily separable diastereoisomers; the 1(S)-auxiliary induces (R)-stereochemistry at the 2-position and the 1(R)-auxiliary provides the antipodal series (see Tetrahedron:Asymmetry, 1991, 2, 1263 and Tetrahedron, 1992, 48, 9707). N-Deprotection may be effected as above for the case wherein P^2 is benzyl, thus providing either the preferred 2(R)- or the 2(S)-enantiomer of (XA) respectively.

25 Again, catalytic hydrogenation of these enantiomers should lead to the (2R,4S)- and (2S,4R)-piperidine enantiomers respectively.

Alternative approaches to these piperidine enantiomers wherein R^7 is methyl, and also to the corresponding (2R,4R)- and (2S,4S)-enantiomers, are described in Biochem.Biophys.Res.Comm., 1981, 101, 440, in which classical
30 fractional distillation, fractional crystallisation of salts formed from optically active acids (L- and D-tartaric acid) and epimerisation techniques are employed.

Resolution may also be achieved by chromatographic separation procedures. For example, acid-catalysed hydrolysis of the cycloadduct formed from (XIX) wherein P^2 is benzyl, and (XX), affords 1-benzyl-4-methyl-1,2,3,6-tetrahydropyridine-2(R,S)-carboxylic acid which is then esterified under standard conditions with a chiral alcohol, e.g. a N-protected ephedrine derivative such as N-acetyl-(1R,2S)-ephedrine. N-Deprotection using, for example, 2,2,2-trichloroethyl chloroformate followed by zinc dust as described above, followed by chromatography on silica gel, furnishes the individual 2(R)- and 2(S)-diastereoisomeric esters, each of which is processed as followed. N-Reprotection, e.g. using a Boc group, removal of the chiral auxiliary by base-catalysed hydrolysis, reesterification with R^8OH , and removal of the Boc group, provides the 2(R)- and 2(S)-enantiomers of (XA) whose identities can be confirmed by comparison with the enantiomers obtained by the asymmetric aza Diels-Alder chemistry previously described.

An alternative approach for assembling a compound of formula (VIII) may involve the sulphonylation of a compound of formula (XXI):




wherein Y and R^8 are as previously defined for formula (VIII), with a compound of formula (XIII), under the conditions employed for reacting (XIII) with (XII).

A compound of formula (XXI) may be prepared from a compound of formula (XXII):

5

10



wherein P is as previously defined for formula (XVI) and Y and R⁸ are as
15 previously defined for formula (XXI), by analogy with the reactions involved in
the conversion of (XVI) to (XIV), followed by N-deprotection as already
described for the conversion of (III) to (II).

A compound of formula (XXII) may be prepared by coupling the
appropriately N-protected 3-(3-pyridyl)alanine with a compound of formula (X),
20 using the conditions already described for coupling (X) with (IX). In a preferred
process, the reagents employed are 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide, 1-hydroxybenzotriazole and N-methylmorpholine, in
dichloromethane as solvent, at from about 0°C to about room temperature.

The bicyclic amines of formula (XVIII) and intermediates employed in the
25 preparation thereof, when neither commercially available nor subsequently
described, can be obtained either by analogy with the processes described in
the Preparations section or by conventional synthetic procedures, in
accordance with standard textbooks on organic chemistry or literature
precedent, from readily accessible starting materials using appropriate
30 reagents and reaction conditions.

Moreover, persons skilled in the art will be aware of variations of, and
alternatives to, those processes described hereinafter in the Examples and
Preparations sections which allow the compounds defined by formula (I) to be
obtained.

-21-

The pharmaceutically acceptable acid addition salts of the compounds of formula (I) may also be prepared in a conventional manner. For example a
5 solution of the free base is treated with the appropriate acid, either neat or in a suitable solvent, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts can be obtained in an analogous manner by treating a solution of a compound of formula (I) with the appropriate base. Both
10 types of salt may be formed or interconverted using ion-exchange resin techniques.

The biological activities of the compounds of the present invention were determined by the following test methods.

15 Chromogenic Assays

The inhibition of thrombin, trypsin, plasmin or factor Xa is measured in 96 well plate chromogenic assays. The percentage inhibition and IC_{50} are calculated from triplicate samples of an 8 concentration dose-response curve. From the substrate K_m and IC_{50} , the K_i for each inhibitor is calculated. All
20 assays are carried out in a total incubation of 200 μ l of 50mM HEPES and 150mM NaCl at pH 8.0, and all compound dilutions are preincubated with enzyme at room temperature for 15 minutes prior to addition of substrate. After 30 minutes incubation at 30°C, the O.D. is measured at 405 nm in a 96 well plate reader. Thrombin activity is measured using bovine thrombin and S2238
25 (H-D-Phe-Pip-Arg-pNA), bovine pancreatic trypsin is assayed with S2222 (Benz-Isoleu-Glu-Gly-Arg-pNA), bovine plasma plasmin is assayed with Chromozym PL (Tosyl-Gly-Pro-Lys-pNA) and bovine factor Xa is assayed in 50mM Tris, 150mM NaCl, pH 7.5 buffer with S2222.

Clotting Assays

30 Thrombin time (TT) and activated partial thromboplastin time (APTT) are measured using Instrumentation Laboratories (IL) Test TT reagent and IL Test APTT (ellagic acid) reagent respectively in an Automated Coagulation Laboratory (ACL), according to the manufacturer's instructions.

-22-

In Vitro

To 1ml aliquots of rat pooled plasma (citrated), a 1/100 volume of a range
5 of compound concentrations is added and preincubated at room temperature
for 15 minutes, after which the TT and APTT are measured.

Ex Vivo

Compounds are dosed per os, intravenously or intraduodenally to rats.
Pre- and post-dose blood samples are taken into citrate solution and plasma
10 prepared. TT and APTT are measured as for in vitro assays.

In therapy, the compounds of formula (I), their pharmaceutically
acceptable salts, and pharmaceutically acceptable solvates of either entity, can
be administered alone, but will generally be administered in admixture with a
15 pharmaceutical carrier selected with regard to the intended route of
administration and standard pharmaceutical practice. Preferably, they are
administered orally in the form of tablets containing such excipients as starch
or lactose, or in capsules or ovules either alone or in admixture with excipients,
or in the form of elixirs, solutions or suspensions containing flavouring or
20 colouring agents. They can also be injected parenterally, for example
intravenously, intramuscularly or subcutaneously. For parenteral
administration, they are best used in the form of a sterile aqueous solution
which may contain other substances, for example enough salts or glucose to
make the solution isotonic with blood. For buccal or sublingual administration
25 they may be administered in the form of tablets or lozenges which can be
formulated in a conventional manner.

For oral, parenteral, buccal and sublingual administration to patients, the
daily dosage level of the compounds of formula (I) and their pharmaceutically
acceptable salts and solvates will be from 1 to 1000 mg (in single or divided
30 doses). Thus tablets or capsules may contain from 0.5 to 500 mg of active
compound for administration singly, or two or more at a time, as appropriate.

-23-

The physician in any event will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and
5 response of the particular patient. The above dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.

Thus the invention provides a pharmaceutical composition comprising a
10 compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, together with a pharmaceutically acceptable diluent or carrier.

The invention also provides a compound of formula (I), or a
pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable
15 solvate of either entity, or a pharmaceutical composition containing any of the foregoing, for use as a medicament.

The invention further includes the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, or a pharmaceutical composition containing any of the
20 foregoing, for the manufacture of a medicament for the curative or prophylactic treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisation trauma, application of lower limb plaster casts, or fractures of the lower limbs or pelvis; recurrent DVT; DVT during pregnancy when there is a previous history thereof; reocclusion
25 following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; disseminated intravascular coagulation; coagulation in extra-corporeal circuits; occlusion of arterio-venous shunts and blood vessel grafts (including coronary artery by-pass grafts);
30 restenosis and occlusion following angioplasty; neurodegenerative disorders; inflammatory disorders; or scarring.

-24-

In a further aspect, the invention provides a method of treating a mammal (including a human being) to cure or prevent deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisation trauma, application of lower limb plaster casts, or fractures of the lower limbs or pelvis; recurrent DVT; DVT during pregnancy when there is a previous history thereof; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; disseminated intravascular coagulation; coagulation in extra-corporeal circuits; occlusion of arterio-venous shunts and blood vessel grafts (including coronary artery bypass grafts); restenosis and occlusion following angioplasty; neurodegenerative disorders; inflammatory disorders; or scarring; which comprises treating said mammal with an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, or a pharmaceutical composition containing any of the foregoing.

The syntheses of the compounds of the invention and of the intermediates for use therein are illustrated by the following Examples and Preparations. The purity of the compounds (Rf) was routinely monitored by thin layer chromatography using Merck Kieselgel 60 F₂₅₄ plates and the following solvent systems (SS):

25

1. hexane:ether, 1:1;
2. ether;
3. dichloromethane:methanol:glacial acetic acid, 90:10:1;
4. hexane:ether, 4:1;
- 30 5. dichloromethane;
6. dichloromethane:methanol:0.880 aqueous ammonia, 95:5:0.5;
7. hexane:ethyl acetate, 3:7;
8. hexane:ethyl acetate, 1:1;

-25-

9. dichloromethane:methanol:0.880 aqueous ammonia, 90:10:1;
10. hexane:ethyl acetate, 3:1;
- 5 11. toluene:ethyl acetate, 4:1;
12. toluene:ethyl acetate, 1:1;
13. isobutyl methyl ketone:glacial acetic acid:water, 2:1:1 (upper phase);
14. ethyl acetate:ethanol, 4:1;
15. ethyl acetate:ethanol:glacial acetic acid, 90:10:0.4;
- 10 16. ethyl acetate:ethanol:glacial acetic acid, 80:20:1;
17. ethyl acetate:ethanol, 9:1;
18. hexane:ethyl acetate:diethylamine, 9:1:0.2;
19. hexane:ethyl acetate, 50:1;
20. dichloromethane:methanol, 97.5:2.5;
- 15 21. dichloromethane:ethanol, 97.5:2.5;
22. hexane:ethyl acetate, 1:4;
23. dichloromethane:methanol, 95:5;
24. dichloromethane:methanol:0.880 aqueous ammonia, 80:20:5;
25. dichloromethane:methanol:0.880 aqueous ammonia, 84:14:2;
- 20 26. ethyl acetate;
27. methanol:ethyl acetate:glacial acetic acid:0.880 aqueous ammonia:water,
60:12:4:4:8;
28. dichloromethane:methanol:0.880 aqueous ammonia, 95:5:1;
29. hexane:ethyl acetate, 1:2.

25

¹H Nuclear magnetic resonance (NMR) spectra were recorded using either a Nicolet QE-300 or a Bruker AC-300 spectrometer and were in all cases consistent with the proposed structures.

Mass spectra were obtained with a Fisons Instrument Trio 1000
30 spectrometer using thermospray ionisation.

Room temperature means 20-25°C.

-26-

EXAMPLE 1

5 4-Methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid dihydrochloride

1M Aqueous sodium hydroxide solution (12.5ml, 12.5 mmol) was added dropwise with stirring to an ice-cooled solution of the title compound of Preparation 25 (1.57g, 2.5 mmol) in water (10ml) and the reaction mixture
10 allowed to warm to room temperature. After 1.5 hours, the solution was extracted with dichloromethane (2 x 15ml) and then acidified to pH2 with 1M hydrochloric acid (13ml). The solution was evaporated to dryness under reduced pressure and residual traces of water removed azeotropically with 2-propanol. The dry residue was extracted with dichloromethane:2-propanol
15 (1:1), then the combined extracts filtered and the filtrate evaporated under reduced pressure to yield the title compound (1.38g, 90%) as a white powder. Rf 0.36 (SS 27). Found: C,48.46; H,6.11; N,12.24. C₂₆H₃₆N₆O₅S; 2HCl; H₂O; 0.33 C₃H₈O; 0.25 CH₂Cl₂ requires C,48.35; H,6.43; N,12.41%.

20

EXAMPLE 2

4-Methyl-1-[N-(3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid dihydrochloride

The title compound (0.6g, 88%) was obtained from the title compound of Preparation 33 (0.7g, 1 mmol), using the procedure of Example 1, as a white
25 powder. Rf 0.27 (SS 27). Found: C,48.93; H,6.76; N,11.84. C₂₇H₃₈N₆O₅S; 2HCl; H₂O; 0.33 C₃H₈O; 0.25 CH₂Cl₂ requires C,49.10; H,6.58; N,12.16%. m/e 559.3 (M+H)⁺.

-27-

EXAMPLE 3

5 4(R)-Methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-carboxylic acid dihydrochloride

The title compound (0.15g, 100%) was obtained from the title compound of Preparation 43 (0.16g, 0.2 mmol), using the procedure of Example 1, as a white powder. Rf 0.33 (SS 27). Found: C,48.06; H,6.67; N,12.00.

10 C₂₆H₃₈N₆O₅S; 2HCl; H₂O; 0.30 C₃H₈O; 0.25 CH₂Cl₂ requires C,48.17; H,6.68; N,12.41%. m/e 547.4 (M+H)⁺.

EXAMPLE 4

15 4-Methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid dihydrochloride

The title compound (496 mg, 84%) was obtained from the title compound of Preparation 62 (576 mg, 0.91 mmol), using the procedure of Example 1, as a white powder. Rf 0.41 (SS27). Found: C,48.07; H,6.31; N,12.74.

20 C₂₆H₃₆N₆O₅S; 2HCl; H₂O; 0.125 CH₂Cl₂ requires C,48.55; H,6.28; N,13.00%. m/e 545 (M+H)⁺.

EXAMPLE 5

25 4(R)-Methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(S)-carboxylic acid dihydrochloride

The title compound (300 mg, 79%) was obtained from the title compound of Preparation 63 (360 mg, 0.57 mmol), using the procedure of Example 1, as a white powder. Rf 0.39 (SS27). Found: C,46.85; H,6.76; N,12.98.

30 C₂₆H₃₈N₆O₅S; 2HCl; 2H₂O; 0.15 CH₂Cl₂ requires C,46.99; H,6.68; N,12.57%.

-28-

EXAMPLE 6

5 4(S)-Methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-
amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-carboxylic acid
dihydrochloride

The title compound (270 mg, 92%) was obtained from the title compound of Preparation 64 (330 mg, 0.48 mmol), using the procedure of Example 1, as a white powder. R_f 0.37 (SS 27). Found: C,46.76; H,6.54; N,12.39.

10 C₂₆H₃₈N₆O₅S; 2HCl; 1.50 H₂O; 0.35 CH₂Cl₂ requires C,46.79; H,6.51; N, 12.43%.

-29-

PREPARATION 12-Trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl chloride

5

(a) 2-Trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline

This intermediate was obtained by the method described in J. Med. Chem., 1980, 23, 837 and used directly in step (b).

- 10 (b) The title compound was also obtained by the method described in J. Med. Chem., 1980, 23, 837, using the intermediate from (a) above, as a white solid (52.9% yield based on 1,2,3,4-tetrahydroisoquinoline), m.p. 104-105°C, after crystallisation from ether. Rf 0.25 (SS 1).

15

PREPARATION 22-Trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-6-sulphonyl chloride

Crystallisation of material recovered from the mother-liquors of Preparation 1(b), from diisopropyl ether, afforded the title compound (3.6% yield based on 1,2,3,4-tetrahydroisoquinoline), m.p. 110-112°C. Rf 0.36 (SS 1).

20

PREPARATION 33-Trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl chloride

25

(a) 2,3,4,5-Tetrahydro-1H-3-benzazepine

This starting material was obtained by the method described in Helv. Chim. Acta, 1935, 18, 1388.

30 (b) 3-Trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine

Trifluoroacetic anhydride (6.0g, 28.56 mmol) was added dropwise over 20 minutes to a stirred, ice-cooled solution of the material from (a) above (4.2g, 28.56 mmol) and N-methylmorpholine (2.89g, 28.56 mmol) in

-30-

dichloromethane (45ml). After 2.5 hours at room temperature, the reaction solution was washed successively with water, 1M aqueous citric acid solution and water, dried (MgSO_4) and evaporated under reduced pressure to yield a yellow solid, which was triturated with hot hexane. Filtration, concentration and cooling of the combined hexane solutions afforded the required product (5.96g) as a pale yellow solid, m.p. 78-80°C. Found: C,58.85; H,4.93; N,5.75. $\text{C}_{12}\text{H}_{12}\text{F}_3\text{NO}$ requires C,59.25; H,4.97; N,5.76%.

(c) Chlorosulphonic acid (10.4ml, 0.156 mol) was added dropwise to a stirred, cold solution of the product from (b) above (5.85g, 11.7 mmol) in dichloromethane, whilst ensuring that the temperature of the reaction mixture was held between -12 and -8°C. After 2 days at room temperature, the reaction solution was poured onto ice and the aqueous phase separated and extracted with dichloromethane. The combined organic extracts were dried (MgSO_4) and evaporated under reduced pressure to provide an oil (7.9g) which was purified by chromatography on silica gel, using a mixture of hexane and ether (1:3) as eluant, to give the title compound as a colourless oil which eventually solidified. Crystallisation of a sample from diisopropyl ether produced a white solid, m.p. 87-88°C. Found: C,41.75; H,3.18; N,3.92. $\text{C}_{12}\text{H}_{11}\text{Cl F}_3\text{NO}_3\text{S}$ requires C,42.17; H,3.24; N,4.10%.

PREPARATION 4

1(R,S)-Methoxymethyl-2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl chloride

30 (a) N-Methoxyacetyl-2-phenylethylamine

Methoxyacetyl chloride (19.57g, 0.18 mol) was added over 10 minutes to a stirred, ice-cooled solution of 2-phenylethylamine (21.85g, 0.18 mol)

-31-

and N-ethyldiisopropylamine (23.26g, 0.18 mol) in dichloromethane (200ml). After 2 hours at room temperature, the solvent was removed under reduced pressure and the residue partitioned between ether and water. The organic phase was washed successively with 1M aqueous citric acid solution, water, saturated aqueous sodium bicarbonate solution and water, dried (MgSO_4) and evaporated under reduced pressure to provide the required product (29.65g) as an oil, Rf 0.32 (SS 2), which was used without further purification in the next step.

(b) 1-Methoxymethyl-3,4-dihydroisoquinoline

Phosphorous pentoxide (25g, 0.176 mol) was added to a stirred solution of the product from (a) above (14.47g, 0.075 mol) in xylene (35ml) and the resulting mixture heated under reflux for 2.5 hours. The solvent was decanted from the resulting black gum which was triturated with xylene and then, when cool, with ether. Water was then carefully added, with ice-cooling, and the resulting mixture basified with 2M aqueous sodium hydroxide solution and then extracted with ether. The extract was washed with water, dried (MgSO_4) and evaporated under reduced pressure to give a brown oil (13.4 g) which was purified by chromatography on silica gel, using ether as eluant, to afford the required compound (5.88g) as an orange oil. Rf 0.28 (SS 2).

(c) 1(R,S)-Methoxymethyl-1,2,3,4-tetrahydroisoquinoline

Sodium triacetoxymethylborohydride (8.11g, 38.3 mmol) was added to a stirred, ice-cooled solution of the product from (b) above (6.1g, 34.8 mmol) in methanol (80ml), then the resulting mixture stirred for 18 hours at room temperature before being quenched with water. The bulk of the solvent was removed under reduced pressure, then the residue basified with 1M aqueous sodium hydroxide solution and extracted with dichloromethane.

-32-

The extract was washed with saturated brine, dried (MgSO_4) and evaporated under reduced pressure to furnish the required product (6.19g) as an orange oil, R_f 0.25 (SS 3), m/e 178 ($M+H$)⁺, which was used without further purification in the next step.

- (d) 1(R,S)-Methoxymethyl-2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline
Trifluoroacetic anhydride (10.26ml, 72.6 mmol) was added dropwise over 0.5 hour to a stirred, ice-cooled solution of the product from (c) above (12.26g, 69.17 mmol) and N-methylmorpholine (7.35 g, 72.6 mmol) in dichloromethane (150ml). After 2 hours at room temperature, the solvent was removed under reduced pressure and the residue partitioned between ether and water. The organic phase was washed successively with water basified to pH ca. 8 with sodium bicarbonate, 1M aqueous citric acid solution and water, dried (MgSO_4) and evaporated under reduced pressure to provide an oil (19.45g) which was purified by chromatography on silica gel, using a mixture of hexane and ether (4:1) as eluant, to give the required compound (16.16g) as a clear oil. R_f 0.27 (SS 4). Found: C,56.83; H,5.19; N,5.02. $\text{C}_{13}\text{H}_{14}\text{F}_3\text{NO}_2$ requires C,57.14; H,5.16; N,5.12%.
- (e) The title compound was obtained from the product of (d) above, using the method of Preparation 3(c), as a pale yellow oil which solidified when chilled. R_f 0.35 (SS 5).

PREPARATION 5

1(R,S)-(N,N-Dimethylcarbamoylmethyl)-2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl chloride

- (a) 1(R,S)-(N,N-Dimethylcarbamoylmethyl)-2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline
1-Ethoxycarbonylmethyl-1,2,3,4-tetrahydroisoquinoline (13.15g, 60 mmol), obtained by the method described in J. Org. Chem., 1965, 30,

-33-

3667, was dissolved in a 30% solution of dimethylamine in ethanol (100ml). Dimethylamine (32g) was added and the reaction mixture heated in a steel bomb at 120°C for 24 hours and at 150°C for a further 24 hours, then evaporated under reduced pressure to provide the required crude amide (12.9g) as an oil, Rf 0.13 (SS 3) plus trace of ester starting material at Rf 0.33, which was used without further purification in the next step.

Trifluoroacetic anhydride (12.12g, 72 mmol) was added dropwise over 0.5 hour to a stirred, ice-cooled solution of the crude amide (12.9g) and N-ethyl-diisopropylamine (10.34g, 80 mmol) in dichloromethane (120ml). After 3 hours at room temperature, the solvent was removed under reduced pressure and the residue partitioned between ether and water. The organic phase was washed successively with water, 5% aqueous sodium bicarbonate solution, 1M aqueous citric acid solution and water, dried (MgSO₄) and evaporated under reduced pressure to give an orange oil which was purified by chromatography on silica gel, using a mixture of hexane and ethyl acetate (3:7) as eluant, to furnish the required compound (14.3g). Rf 0.35 (SS 7). Found: C, 56.88; H, 5.38; N, 8.85. C₁₅H₁₇F₃N₂O₂ requires C, 57.32; H, 5.45; N, 8.91%.

(b) The title compound (84% yield) was obtained from the product of (a) above, using the procedure of Preparation 3(c), as a white foam. Rf 0.47 (SS 7).

PREPARATION 6

5-Methyl-2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-8-sulphonyl chloride

30

(a) 5-Methylisoquinoline

A 3M solution of methyl magnesium iodide in ether (50ml, 0.15 mol) was added dropwise to a stirred, ice-cooled solution of 5-bromoisoquinoline

-34-

(21g, 0.10 mol), obtained by the method described in J. Org. Chem., 1964, 29, 329, and [1,3-bis(diphenylphosphino)propane]nickel(II) chloride (400mg, 0.7 mmol) in anhydrous ether and the reaction mixture heated under reflux for 5 days, allowed to cool, then poured into water (500ml). The organic phase was separated, combined with ether extracts of the aqueous phase, washed with saturated brine, dried (MgSO_4) and evaporated under reduced pressure to yield an oil, chromatography of which on silica gel, using a 5-50% ether in hexane elution gradient, provided the required product (8.4g). R_f 0.40 (SS 8), m/e 144 ($M+H$)⁺. Found: C,79.57; H,6.26; N,8.61. $C_{10}H_9N$; 0.27 $C_4H_8O_2$ requires C,79.70; H,6.74; N,8.39%.

However, the major component of the chromatographic purification procedure was a mixture (18.4g) of product and starting material which, on crystallisation from hexane, afforded a 2:1 mixture (14.8g) of 5-bromoisoquinoline and 5-methylisoquinoline.

(b) A stirred, ice-cooled solution of the above 2:1 mixture (14.3g) in dichloromethane (150ml) was saturated with hydrogen chloride and then evaporated under reduced pressure to afford the corresponding hydrochloride salt which was collected and dried.

A stirred mixture of platinum oxide (1g) and a solution of the preceding hydrochloride salt in ethanol (150ml) was hydrogenated for 30 hours at 50 psi (3.45 bar) and room temperature, then filtered. The filtrate was evaporated under reduced pressure and the residue chromatographed on silica gel, using a mixture of dichloromethane:methanol: 0.880 aqueous ammonia solution (90:10:1) as eluant, to give an 85:15 mixture (5.62g) of 5-methyl-1,2,3,4-tetrahydroisoquinoline and 5-bromo-1,2,3,4-tetrahydroisoquinoline as an oil; major component: R_f 0.32 (SS 9), m/e 148 ($M+H$)⁺.

-35-

The above 85:15 mixture was converted to the corresponding 2-trifluoroacetyl derivative mixture, using the procedure described in Preparation 3(b), to afford an oil; major component: Rf 0.90 (SS 10), m/e 244 (M+H)⁺.

The above crude mixture containing 85% of 5-methyl-2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline, was chlorosulphonated following the procedure described in Preparation 3(c) to provide a yellow solid which, on purification by chromatography on silica gel using an elution gradient of 10-50% ethyl acetate in hexane, gave the title compound as a white solid, m.p. 152-153°C. Found: C,42.18; H,3.24; N,4.10. C₁₂H₁₁Cl F₃NO₃S requires C,42.12; H,3.10; N,3.85%.

15

PREPARATION 7

N-t-Butoxycarbonyl-3-(3-pyridyl)-(S)-alanine

Anhydrous potassium carbonate (7.5g, 54 mmol) was added to a stirred, ice-cooled suspension of 3-(3-pyridyl)-(S)-alanine (Int. J. Pept. Prot. Res.; 1987, 29, 118; 9g, 54 mmol) in water (50ml), followed by the dropwise addition of a solution of di-t-butyl dicarbonate (18g, 82 mmol) in 1,4-dioxan (25ml) over 10 minutes. The resulting mixture was allowed to warm to room temperature and stir for 18 hours. The reaction mixture was concentrated by evaporation of the bulk of the 1,4-dioxan under reduced pressure and extracted with ethyl acetate (2 x 20ml). The pH of the aqueous solution was adjusted to ca. 3 with solid citric acid, solid sodium chloride added to saturation and extraction with ethyl acetate (5 x 20ml) effected. The combined organic extracts were dried (MgSO₄), filtered and evaporated to low bulk under reduced pressure, whereupon the product started to crystallise. After chilling at 0°C for 1 hour, the crystals were collected, washed with ether and dried to give the required product (10.36g, 72%). Rf 0.3⁺ (SS 13).

²⁵
[α]_D²⁵ +10° (c=0.1, CH₃OH). Found: C,58.69; H,7.17; N,10.50. C₁₃H₁₈N₂O₄ requires C,58.63; H,6.81; N,10.52%.

-36-

PREPARATION 8N-t-Butoxycarbonyl-3-(3-pyridyl)-(S)-alanine t-butyl ester

5 To a stirred, ice-cooled solution of the title compound of Preparation 7 (10g, 37.5 mmol) and t-butanol (14g, 189 mmol) in dichloromethane (100ml) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (10g, 52 mmol) and 4-dimethylaminopyridine (2.3g, 18.8 mmol). The reaction mixture was allowed to warm to room temperature and stir for 18 hours. The solvent
10 was evaporated under reduced pressure and the residue dissolved in ethyl acetate (100ml). This solution was washed with water (2 x 30ml) and brine (20ml), dried (MgSO₄), filtered and evaporated under reduced pressure to yield an oil, which was purified by chromatography on silica gel using ethyl acetate:hexane (1:1) as eluant to afford the title compound (12.2g, 100%) as a
15 clear oil. R_f 0.59 (SS 26). m/e 322.9 (M+H)⁺.

PREPARATION 9N-t-Butoxycarbonyl-3-(1-benzyl-3-pyridinium)-(S)-alanine t-butyl ester bromide

To a stirred solution of the title compound of Preparation 8 (1g, 3.1 mmol)
20 in dry ethanol (10ml) at room temperature was added a solution of benzyl bromide (0.79g, 4.6 mmol) in dry ethanol (2ml), dropwise, over 5 minutes. After 18 hours the ethanol was evaporated under reduced pressure. The residue was dissolved in acetonitrile (10ml) and the solution was extracted with hexane (3 x 5ml) and then evaporated to dryness under reduced pressure. Solvent
25 traces were removed azeotropically with dichloromethane to furnish the required product (1.23g, 96%) as a white foam. R_f 0.49 (SS 13). Found: C, 56.40; H, 7.07; N, 5.10. C₂₃H₃₃BrN₂O₄; 0.17 CH₂Cl₂ requires C, 56.14; H, 6.77; N, 5.65%.

-37-

PREPARATION 10N-t-Butoxycarbonyl-3-(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanine t-5 butyl ester

Sodium borohydride (0.19g, 5 mmol) was added in two equal portions over 5 minutes to a stirred, ice-cooled solution of the title compound of Preparation 9 (0.7g, 1.7 mmol) in ethanol (10ml). After 1.5 hours, the solution was evaporated to dryness under reduced pressure. The residue was
10 dissolved in dichloromethane (20ml) and the solution was washed with saturated aqueous sodium bicarbonate solution and brine, dried (MgSO₄), filtered and evaporated under reduced pressure. The residue was purified by chromatography on silica gel, using an elution gradient of ethyl acetate:hexane (0:100 to 20:80), to afford the title compound (0.36g, 91%) as an oil. R_f 0.42
15 (SS 8). m/e 417.3 (M+H)⁺.

PREPARATION 113-(1-Benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanine t-butyl ester

The title compound of Preparation 10 (1g, 2.4 mmol) was dissolved in
20 96% formic acid (10ml) and the solution was stirred at room temperature for 4 hours. The formic acid was then removed under reduced pressure at $\leq 30^{\circ}\text{C}$. The residue was dissolved in 1M aqueous citric acid solution (20ml) and the solution extracted with ethyl acetate (2 x 10ml). The aqueous phase was basified to pH8 with solid sodium bicarbonate and extracted with
25 dichloromethane (3 x 10ml). The combined organic extracts were dried (MgSO₄), filtered and evaporated under reduced pressure to yield the required product (0.74g, 97%) as an oil, which was used without further purification. R_f 0.73 (SS 9).

-38-

PREPARATION 12

5 N-(2-Trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanine t-butyl ester

2-Trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl chloride (Preparation 1; 2.26g, 6.9 mmol) was added dropwise over 5 minutes as a solution in dichloromethane (5ml) to a stirred, ice-cooled solution of the title compound of Preparation 11 (1.82g, 5.7 mmol) and N-ethyldiisopropylamine (1.1g, 8.5 mmol) in dichloromethane (10ml). The resulting solution was allowed to warm to room temperature and stir for 18 hours. The solvent was evaporated under reduced pressure and the residue dissolved in ethyl acetate (30ml). This solution was washed with water (10ml), saturated aqueous sodium bicarbonate solution (2 x 10ml) and saturated brine (10ml), dried (MgSO₄),
15 filtered and evaporated under reduced pressure. The residue was purified by chromatography on silica gel, using an elution gradient of ethyl acetate:hexane (10:90 to 50:50), to furnish the required product (3g, 86%) as a white foam. R_f 0.63 (SS 26). Found: C,58.70; H,5.75; N,6.64. C₃₀H₃₆F₃N₃O₅S; 0.10 CH₂Cl₂ requires C,58.66; H,5.92; N,6.82%. m/e 608.4 (M+H)⁺.

20

PREPARATION 13

N-(2-Trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanine hydrochloride

A stirred, ice-cooled solution of the title compound of Preparation 12 (3g, 4.9 mmol) in dichloromethane (30ml) was saturated with hydrogen chloride and then allowed to attain room temperature. After 6 hours the solvent and excess hydrogen chloride were removed under reduced pressure. Residual traces of hydrogen chloride were removed azeotropically with dichloromethane to yield the title compound (3g, 100%) as a white foam. R_f 0.29 (SS 13). Found:
30 C,50.40; H,4.90; N,6.73. C₂₆H₂₇F₃N₃O₅S; HCl; 0.50 CH₂Cl₂ requires C,50.47; H,4.79; N,6.66%. m/e 552.4 (M+H)⁺.

-39-

PREPARATION 144(R)-Methylpiperidine-2(R)-carboxylic acid ethyl ester

- 5 The title compound was obtained by the method described in Biochem. Biophys. Res. Comm., 1981, 101, 440.

PREPARATION 154-Methyl-1.2.3.6-tetrahydropyridine-2(R)-carboxylic acid ethyl ester

10 hydrochloride

- (a) 4-Methyl-1-[1-(S)-phenylethyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid ethyl ester

15 This intermediate was obtained by the method described in Tetrahedron:Asymmetry, 1991 2, 1263.

- (b) A stirred solution of the above intermediate (13.56g, 49.7 mmol) in toluene (150ml), under nitrogen, was heated under reflux for 2 hours, using a Dean-Stark trap. 1,8-Bis(dimethylamino)naphthalene (1.08g, 5.0 mmol) was then added, heating continued for a further 1 hour, the reaction mixture allowed to cool and the Dean-Stark trap removed. After the addition of 1-chloroethyl chloroformate (10.7ml, 14.2g, 99.5 mmol), the reaction mixture was stirred under reflux for 16 hours, allowed to cool, treated with absolute ethanol (80ml), stirred under reflux for 2 hours more and evaporated under reduced pressure. The residue was partitioned between ethyl acetate (100ml) and 1M hydrochloric acid (50ml), then the aqueous phase separated, neutralised with solid sodium bicarbonate and extracted with dichloromethane (3 x 200ml). Evaporation under reduced pressure of the dried (MgSO₄), combined extracts provided a brown residue which was purified by chromatography on silica gel, using a 0-5% methanol in dichloromethane elution gradient, and then converted to the

-40-

required hydrochloride salt using excess ethereal hydrogen chloride. The product was further purified by dissolution in dichloromethane (20ml), filtration (to remove residual silica gel), dilution of the filtrate with ether (200ml), filtration, washing of the precipitate with ether and drying in vacuo. A sample of this purified product (5.77g) was crystallised from a mixture of ether and ethanol to afford the title compound as white crystals, m.p. 110-111°C. Rf 0.35 (SS 3).

$[\alpha]_D^{25} +113.7^\circ$ (c=1.0, CH₃CH₂OH). Found: C,52.79; H,7.94; N,6.68. C₉H₁₅NO₂; HCl requires C,52.55; H,7.84; N,6.81%.

PREPARATION 16

4-Methyl-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester p-toluenesulphonate

(a) 4-Methyl-1-[1-(S)-phenylethyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester

This intermediate was obtained by the method described in Tetrahedron, 1992, 48, 9707 as the major diastereoisomer of a mixture also containing the 1(S), 2(S)-diastereoisomer (ratio 3.7:1 by NMR spectroscopy).

Formation of the hydrochloride salt using hydrogen chloride in toluene. followed by two crystallisations from ethyl acetate and liberation of the free base, afforded the required 1(S),2(R)-diastereoisomer in sufficiently stereochemically pure form (S,R:S,S > 97:3) for further processing.

(b) N-Deprotection of the previous product was effected by the methodology described in J. Org. Chem., 1984, 49, 2081, (see also Preparation 21), using 1-chloroethyl chloroformate as the "debenzylation" reagent, followed by conversion of the resulting hydrochloride salt to the corresponding p-toluenesulphonate, m.p. 141-143°C. Rf 0.61 (SS 9).

-41-

PREPARATION 174-Methyl-1,2,3,6-tetrahydropyridine-2(R,S)-carboxylic acid ethyl ester5 hydrochloride

(a) 1-Benzyl-4-methyl-1,2,3,6-tetrahydropyridine-2(R,S)-carboxylic acid ethyl ester

10 This intermediate was obtained by the method described in Tetrahedron Asymmetry, 1991, 2, 1263.

(b) The title compound (82% yield) was obtained from the intermediate of (a) above, using the method of Preparation 15(b), as a white solid, m.p. 130-130.5°C. Rf 0.35 (SS 3).

15

PREPARATION 184-Methyl-1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid ethyl esterhydrochloride

20 (a) 1-Benzyl-4-methyl-1,2,3,6-tetrahydropyridine-2(R,S)-carboxylic acid hydrochloride

25 A stirred solution of 1-benzyl-4-methyl-1,2,3,6-tetrahydropyridine-2(R,S)-carboxylic acid ethyl ester (Preparation 17(a); 20.1g, 77.5 mmol) in 5M hydrochloric acid (200ml) was heated at 100°C for 4.5 hours and then evaporated to dryness under reduced pressure. Residual water was removed azeotropically using dichloromethane followed by toluene to give the required product (24.0g) as a white foam, Rf 0.40 (SS 13), which was used without further purification in the next step.

-42-

(b) 1-Benzyl-4-methyl-1,2,3,6-tetrahydropyridine-2(R,S)-carboxylic acid N-acetyl-(1R,2S)-ephedrine ester

5 1,3-Dicyclohexylcarbodiimide (20.6g, 0.1 mol) was added to a stirred solution of the product from (a) above (24.0g, 89.6 mmol), N-acetyl-(1R,2S)-ephedrine (18.47g, 89.2 mmol), obtained by the method described in J. Amer. Pharmaceut. Assoc., 1952, 41, 545, (see J. Med. Chem., 1965, 8, 466), N-ethyldiisopropylamine (12.9g, 0.1 mmol) and 4-
10 dimethylaminopyridine (9.51g, 77.5 mmol) in dichloromethane (250ml). After 3 days at room temperature, the reaction mixture was filtered and the filtrate evaporated to dryness under reduced pressure. The residue was partitioned between ethyl acetate and water, then the organic phase separated, washed with water, dried (MgSO_4) and evaporated under
15 reduced pressure to give the crude product, which was purified by chromatography on silica gel, using ether as eluant, to furnish the required pure product (25.5g) as an oil. Rf 0.35 (SS 2). Found: C,73.34; H,7.71; N,5.73. $\text{C}_{26}\text{H}_{32}\text{N}_2\text{O}_3$; 0.30 $\text{C}_4\text{H}_{10}\text{O}$ requires C,73.78; H,7.91; N,6.33%.

20 (c) 4-Methyl-1-(2,2,2-trichloroethoxycarbonyl)-1,2,3,6-tetrahydropyridine-2(R,S)-carboxylic acid N-acetyl-(1R,2S)-ephedrine ester

Sodium bicarbonate (11.21g, 133 mmol), then 2,2,2-trichloroethyl chloroformate (11.7ml, 17.97g, 84.8 mmol), were added to a stirred
25 solution of the product from (b) above (25.48g, 60.6 mmol) in dry dichloromethane (200ml) and the resulting mixture was heated under reflux for 22 hours. The solvent was removed under reduced pressure and the residue partitioned between ethyl acetate and water. The separated organic phase was washed with saturated brine, dried (MgSO_4) and evaporated under reduced pressure, then the residue purified by
30 chromatography on silica gel, using ether as eluant, to afford the required product (28.1g) as a gum. Rf 0.40 (SS 2). Found: C,52.10; H,5.38; N,5.24. $\text{C}_{22}\text{H}_{27}\text{Cl}_3\text{N}_2\text{O}_5$ requires C,52.24; H,5.38; N,5.54%.

-43-

- (d) 4-Methyl-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid N-acetyl-(1R,2S)-ephedrine ester and 4-methyl-1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid N-acetyl-(1R,2S)-ephedrine ester

1M Aqueous potassium dihydrogen phosphate solution (40ml, 40 mmol), then zinc dust (40g, 610 mmol), were added to a rapidly stirred solution of the product from (c) above (32.9g, 65 mmol) in tetrahydrofuran (200ml). After 1 hour at room temperature, the reaction mixture was filtered and the bulk of the organic solvent removed under reduced pressure, then the residue basified with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The extract was washed with saturated brine, dried (MgSO₄) and evaporated under reduced pressure to give an oil (21.46g), which was chromatographed on silica gel using an elution gradient of ethanol:ethyl acetate (1:4 to 3:7), to provide firstly the 2(R)-diastereoisomeric ester (2.75g), R_f 0.30 (SS 14), m/e 331 (M+H)⁺, followed by the 2(S)-diastereoisomeric ester (2.90g), R_f 0.22 (SS 14), m/e 331 (M+H)⁺, each as a pale yellow oil.

- (e) N-t-Butoxycarbonyl-4-methyl-1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid N-acetyl-(1R,2S)-ephedrine ester

Di-t-butyl dicarbonate (4.4g, 20.2 mmol) was added to a stirred solution of the 2(S)-ester product from (d) above (5.13g, 15.5 mmol) and N-methylmorpholine (2.04g, 20.2 mmol) in dichloromethane (40ml). After 5 hours at room temperature, more di-t-butyl dicarbonate (1.35g, 6.2 mmol) was added and the reaction mixture stirred for a further 15 hours before removal of the solvent under reduced pressure. The residual mixture was partitioned between ethyl acetate and water, then the organic phase washed successively with 1M aqueous citric acid solution, saturated aqueous sodium bicarbonate solution and saturated brine, dried (MgSO₄)

-44-

and evaporated under reduced pressure to give a gum which was purified by chromatography on silica gel, using ether as eluant, to afford the required product (6.02g) as a gum. Rf 0.45 (SS 2). Found: C,66.84; H,7.97; N,6.50. $C_{24}H_{34}N_2O_5$ requires C,66.95; H,7.96; N,6.51%.

(f) N-t-Butoxycarbonyl-4-methyl-1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid

1M Aqueous sodium hydroxide solution (69ml, 69 mmol) was added to a stirred solution of the product from (e) above (5.97g, 13.9 mmol) in 1,4-dioxan (60ml). After 3 hours at room temperature, solid citric acid (5.53g, 26 mmol) was added and the bulk of the solvent removed under reduced pressure. The residual suspension was basified to pH 10 with 1M aqueous sodium hydroxide solution, washed with dichloromethane, acidified to pH 3 with solid citric acid and extracted with ethyl acetate. The organic extract was washed with saturated brine, dried ($MgSO_4$) and evaporated under reduced pressure to provide the required product (3.47g) as a gum. Rf 0.60 (SS 17).

(g) N-t-Butoxycarbonyl-4-methyl-1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid ethyl ester

1,3-Dicyclohexylcarbodiimide (4.3g, 20.8 mmol) was added to a stirred solution of the product from (f) above (3.35g, 13.9 mmol), ethanol (4.1ml, 69.4 mmol) and 4-dimethylaminopyridine (1.7g, 13.9 mmol) in dichloromethane (40ml). After 18 hours at room temperature, glacial acetic acid (0.4 ml) was added and the reaction mixture stirred for a further 0.5 hour before being filtered. The residue obtained by evaporation of the filtrate under reduced pressure was partitioned between ether and water, then the organic phase washed successively

-45-

with 1M aqueous citric acid solution, saturated aqueous sodium bicarbonate solution and saturated brine, dried (MgSO_4) and evaporated under reduced pressure to give an oil (5.15g), which was purified by chromatography on silica gel, using hexane:ether (4:1) as eluant, to furnish the required product (3.4g) as a clear oil. R_f 0.30 (SS 4). m/e 270 ($M+H$)⁺.

(h) A stirred, ice-cooled solution of the product from (g) above (3.13g, 11.62 mmol) in ethyl acetate (30ml) was saturated with hydrogen chloride over 0.5 hour and then stood at room temperature for a further 2 hours. The solvent was evaporated under reduced pressure and the residue crystallised from a mixture of ether and ethanol to afford the title compound (2.20g) as white crystals, m.p. 108-109°C. R_f 0.35 (SS 3), $[\alpha]_D^{25}$ -106.5°C ($c = 1.0$, $\text{CH}_3\text{CH}_2\text{OH}$). Found: C, 52.49; H, 7.90; N, 6.70. $\text{C}_9\text{H}_{15}\text{NO}_2$; HCl requires C, 52.55; H, 7.84; N, 6.81%.

The compound obtained by carrying out steps (e), (f), (g) and (h) on the 2(R)-ester from (d) above was found to be identical with the title compound of Preparation 15.

PREPARATION 19

4-Ethyl-1,2,3,6-tetrahydropyridine-2(R,S)-carboxylic acid ethyl ester hydrochloride

(a) 2-Cyano-4-ethyl-1-methyl-1,2,3,6-tetrahydropyridine hydrochloride
Methyl iodide (74.7 ml, 170.33g, 1.22 mol) was cautiously added portionwise to a stirred solution of 4-ethylpyridine (107.2g, 1 mol) in acetone (500ml), the resulting mixture heated under reflux for 2 hours and allowed to cool, then a portion of solvent (ca. 100ml) removed under reduced pressure. Addition of ether (1.0 l), collection and washing with ether of the precipitate, followed by drying in vacuo, provided the required quaternary iodide (245g) as a very hygroscopic solid.

-46-

5 6M Hydrochloric acid (130ml) was slowly added to a stirred solution of potassium cyanide (130g, 2.5 mol) in water (260ml) covered by a layer of ether (400ml), ensuring that the temperature was maintained below 15°C. Successive, portionwise addition of the above quaternary salt (139.49g, 0.56 mol) and sodium borohydride (27g, 0.71 mol) over 15 minutes gave a milky mixture, which was stirred at ca. 10°C for 0.5 hour and then at room temperature for a further 4 hours. The ether phase was removed by
10 suction and combined with an ether extract of the aqueous phase, then washing with saturated brine and drying (MgSO₄) effected. The ether solution was ice-cooled, with stirring, and methyl iodide (6ml) added to precipitate any unwanted 4-ethyl-1-methylpiperidine as the derived quaternary iodide. Filtration, followed by treatment of the filtrate with
15 excess 1M ethereal hydrogen chloride, afforded the required product (43.77g) as an oil, R_f 0.20 (SS 18), which was used without further purification in the next step.

(b) 4-Ethyl-1-(2,2,2-trichloroethoxycarbonyl)-1,2,3,6-tetrahydropyridine-
20 2(R.S)-carboxylic acid ethyl ester
A stirred solution of the product from (a) above (43.5g, 0.23 mol) in ethanol (100ml) was saturated with hydrogen chloride, heated under reflux for 6.5 hours and then evaporated to dryness under reduced pressure. The residue was basified with aqueous sodium carbonate solution, then
25 extraction with ethyl acetate effected. The extract was washed with saturated brine, dried (MgSO₄) and evaporated under reduced pressure to give the crude ethyl ester, which was partially purified by chromatography on silica gel, using hexane:ethyl acetate: diethylamine (90:5:2) as eluant, to provide an oil (8.0g).

30

-47-

5 Sodium carbonate (10.0g, 94 mmol) and 2,2,2-trichloroethyl chloroformate (13.0g, 61 mmol) were added successively to a stirred solution of the above crude ester (8.0g, 40 mmol) in dichloromethane (200ml) and the resulting mixture heated under reflux for 20 hours, then evaporated under reduced pressure. The residue was partitioned between ethyl acetate and water, then the organic phase dried (MgSO_4) and evaporated under reduced pressure to give an oil which was purified by chromatography on silica gel, using hexane:ethyl acetate (50:1) as eluant, to furnish the required product (4.8g) as a colourless oil. R_f 0.25 (SS 19).

15 (c) 1M Aqueous potassium dihydrogen phosphate solution (70ml, 70 mmol), then zinc dust (46g, 700 mmol), were added to a rapidly stirred solution of the product from (b) above (4.76g, 13.3 mmol) in tetrahydrofuran (220ml). After 2 hours at room temperature more zinc dust (5g, 76 mmol) was added and the reaction mixture stirred for a further hour before being filtered. The filter pad was washed with water and tetrahydrofuran, then the bulk of the organic solvent removed from the combined filtrate and washings. The residual mixture was acidified with 2M hydrochloric acid (30ml), washed with ethyl acetate to remove starting material (2.32g recovered), neutralised with solid potassium carbonate and extracted with dichloromethane. The combined organic extracts were washed with saturated brine, dried (MgSO_4), treated with excess ethereal hydrogen chloride and evaporated under reduced pressure. Purification of the residue by chromatography on silica gel, using dichloromethane:methanol (95:5) as eluant, furnished the title compound (330mg), as a colourless waxy solid. m/e 184 ($\text{M}+\text{H}$)⁺.

-48-

PREPARATION 20

4-Methyl-1-[N-(2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester

Dimethylformamide (0.25ml) was added in one portion to a stirred, ice-cooled solution of the title compound of Preparation 13 (3g, 5.1 mmol) and oxalyl chloride (2.6g, 20.5 mmol) in dichloromethane (30ml). After 2 hours at room temperature the solvent and excess oxalyl chloride were removed by evaporation under reduced pressure. Residual traces of oxalyl chloride were removed azeotropically with dichloromethane to give the crude acyl chloride as a foam, which was then dissolved in dichloromethane (30ml). To this stirred, ice-cooled solution were added, successively, the title compound of Preparation 16 (1.83g, 5.6 mmol) and N-ethyl-diisopropylamine (2.3g, 17.8 mmol). The resulting solution was stirred at room temperature for 18 hours and then evaporated under reduced pressure. The residue was dissolved in ethyl acetate (50ml) and the solution washed successively with water, saturated aqueous sodium bicarbonate solution and saturated brine, dried (MgSO₄) and evaporated under reduced pressure to give the crude product, which was purified by chromatography on silica gel using an elution gradient of ethyl acetate:hexane (10:90 to 100:0) to afford the title compound (3g, 85%) as a white foam. R_f 0.32 (SS 26). Found C,59.08; H,5.27; N,7.62. C₃₄H₃₉F₃N₄O₆S requires C,59.29; H,5.71; N,8.13%. m/e 689.1 (M+H)⁺.

PREPARATION 21

4-Methyl-1-[N-(2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester

1-Chloroethyl chloroformate (0.93g, 6.5 mmol) was added dropwise as a solution in dichloromethane (3ml) to a stirred, ice-cooled solution of the title compound of Preparation 20 (3g, 4.3 mmol) and 1,8-bis(dimethylamino)-

-49-

naphthalene (0.09g, 0.4 mmol) in dichloromethane (12ml). The resulting solution was allowed to warm to room temperature. After 3 hours the reaction mixture was washed with 1M aqueous citric acid solution (2 x 5ml) and saturated brine (5ml), dried (MgSO_4), filtered and evaporated under reduced pressure. The residue was dissolved in methanol (25ml) and the solution heated to reflux for 45 minutes. The solvent was evaporated under reduced pressure and the crude product purified by chromatography on silica gel, using an elution gradient of dichloromethane:hexane (75:25 to 100:0), followed by dichloromethane:methanol:0.880 aqueous ammonia (99:1:0.5 to 95:5:0.5), to furnish the required product (2g, 76%) as a white foam. Rf 0.24 (SS 9). Found: C, 52.86; H, 5.38; N, 8.65. $\text{C}_{27}\text{H}_{33}\text{F}_3\text{N}_4\text{O}_6\text{S}$; 0.20 CH_2Cl_2 requires C, 53.06; H, 5.46; N, 9.10%. m/e 599 ($\text{M}+\text{H}$)⁺.

PREPARATION 22

4-Methyl-1-{N-[2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester

A stirred, ice-cooled solution of the title compound of Preparation 21 (2g, 3.3 mmol) in dichloromethane (20ml) was treated sequentially with triethylamine (1g, 9.9 mmol), bis t-butoxycarbonyl-S-methylisothiurea (J. Med. Chem., 1993, 36, 2956; 1.05g, 3.6 mmol) and mercuric chloride (1g, 3.7 mmol) and then allowed to warm to room temperature and stir for 18 hours. The reaction mixture was filtered and the filtrate washed successively with water (5ml), 1M aqueous citric acid solution (5ml) and saturated brine (5ml), dried (MgSO_4), filtered and evaporated under reduced pressure. The residue was purified by chromatography on silica gel, using an elution gradient of ethyl acetate:hexane (0:100 to 80:20), to furnish the required product (2.4g, 86%) as a white foam. Rf 0.33 (SS 12). Found: C, 52.11; H, 5.82; N, 9.59. $\text{C}_{38}\text{H}_{51}\text{F}_3\text{N}_6\text{O}_{10}\text{S}$; 0.50 CH_2Cl_2 requires C, 52.34; H, 5.93; N, 9.51%. m/e 841.1 ($\text{M}+\text{H}$)⁺.

-50-

PREPARATION 23

5 4-Methyl-1-{N-[1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester

A solution of sodium carbonate (1.2g, 11.3 mmol) in water (15ml) was added dropwise to a stirred solution of the title compound of Preparation 22 (2.4g, 2.8 mmol) in methanol (25ml) at room temperature. After 1.5 hours the
10 bulk of the methanol was removed under reduced pressure. The remaining aqueous phase was extracted with ethyl acetate (2 x 10ml) and the combined organic extracts were dried (MgSO₄), filtered and evaporated under reduced pressure. The residue was purified by chromatography on silica gel, using an elution gradient of dichloromethane:hexane (75:25 to 100:0), followed by
15 dichloromethane:methanol:0.880 aqueous ammonia (95:5:0.5 to 90:10:1), to give the required product (2.07g, 97%) as a white foam. R_f 0.40 (SS 9).
Found: C,55.22; H,6.72; N,10.65. C₃₆H₅₂N₆O₉S; 0.50 CH₂Cl₂ requires C,55.67; H,6.78; N,10.67%.

20

PREPARATION 24

4-Methyl-1-{N-[2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester

Aqueous formaldehyde solution (37% w/v, 0.9ml, 11 mmol) was added to
25 a stirred solution of the title compound of Preparation 23 (2.07g, 2.7 mmol) in dichloromethane (20ml) at room temperature then, after 20 minutes, sodium triacetoxycrohydride (0.82g, 3.8 mmol) was added. After a further 2 hours, the reaction mixture was washed with saturated aqueous sodium bicarbonate solution (2 x 10ml) and saturated brine (10ml), dried (MgSO₄), filtered and
30 evaporated under reduced pressure. The residue was purified by chromatography on silica gel, using an elution gradient of dichloromethane:hexane (75:25 to 100:0), followed by dichloromethane:

-51-

methanol:0.880 aqueous ammonia (99:1:0.5 to 95:5:0.5), to afford the required product (1.95g, 93%) as a white foam. Rf 0.54 (SS 9). Found: C,55.95;

5 H,7.00; N,10.36. $C_{37}H_{54}N_6O_9S$; 0.50 CH_2Cl_2 requires C,56.19; H,6.92; N,10.48%.

PREPARATION 25

10 4-Methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-amidin-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester dihydrochloride

A stirred, ice-cooled solution of the title compound of Preparation 24 (1.93g, 2.5 mmol) in dichloromethane (30ml) was saturated with hydrogen chloride. The solution was allowed to attain room temperature and after 5
15 hours the solvent and excess hydrogen chloride were removed under reduced pressure. Residual traces of hydrogen chloride were removed azeotropically with dichloromethane to furnish the product (1.57g, 98%) as a white powder. Rf 0.22 (SS 24). Found: C,47.26; H,6.38; N,11.89. $C_{27}H_{38}N_6O_5S \cdot 2HCl \cdot H_2O$; 0.50 CH_2Cl_2 requires C,47.72; H,6.26; N,12.14%.

20

PREPARATION 26

N-(3-Trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl)-3-(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanine t-butyl ester

The title compound (1.9g, 70%) was obtained from the title compounds of
25 Preparation 3 (1.62g, 4.7 mmol) and Preparation 11 (1.36g, 4.3 mmol), using the procedure described in Preparation 12, as a white foam. Rf 0.65 (SS 26). Found C,59.14; H,6.09; N,6.54. $C_{31}H_{38}F_3N_3O_5S$; 0.125 CH_2Cl_2 requires C,59.11; H,6.09; N,6.64%. m/e 622.1 (M+H)⁺.

-52-

PREPARATION 27

5 N-(3-Trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl)-3-(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanine hydrochloride

The title compound (1.85g, 100%) was obtained from the title compound of Preparation 26 (1.89g, 3 mmol), using the procedure described in Preparation 13, as a white foam. Rf 0.35 (SS 13). m/e 566.2 (M+H)⁺.

10

PREPARATION 28

4-Methyl-1-[N-(3-trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl)-3-(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester

15 The title compound (1.7g, 80%) was obtained from the title compounds of Preparation 27 (1.82g, 3.0 mmol) and Preparation 16 (1.1g, 3.3 mmol), using the procedure of Preparation 20, as a white foam. Rf 0.68 (SS 9). Found: C,58.50; H,5.43; N,7.39. C₃₅H₄₁F₃N₄O₆S; 0.10 CH₂Cl₂ requires C,59.10; H,5.83; N,7.87%. m/e 703.3 (M+H)⁺.

20

PREPARATION 29

4-Methyl-1-[N-(3-trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl)-3-(1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester

25 The title compound (1.24g, 78%) was obtained from the title compound of Preparation 28 (1.8g, 2.5 mmol), using the procedure of Preparation 21, as a tan-coloured foam. Rf 0.21 (SS 9). Found: C,53.43; H,5.35; N,8.72. C₂₈H₃₅F₃N₄O₆S; 0.20 CH₂Cl₂ requires C,53.78; H,5.66; N,8.89%. m/e 613.3 (M+H)⁺.

-53-

PREPARATION 30

5 4-Methyl-1-{N-[3-trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl}-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester

The title compound (1.49g, 87%) was obtained from the title compound of Preparation 29 (1.22g, 2 mmol), using the procedure of Preparation 22, as a white foam. Rf 0.84 (SS 26). Found: C,52.72; H,5.81; N,9.36.

10 $C_{39}H_{53}F_3N_6O_{10}S$; 0.50 CH_2Cl_2 requires C,52.86; H,6.06; N,9.36%.

PREPARATION 31

15 4-Methyl-1-{N-[2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl}-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester

The title compound (0.94g, 72%) was obtained from the title compound of Preparation 30 (1.47g, 1.7 mmol), using the procedure of Preparation 23, as a white foam. Rf 0.38 (SS 9). Found: C,56.08; H,7.22; N,10.15. $C_{37}H_{54}N_6O_9S$; 0.50 CH_2Cl_2 requires C,56.19; H,6.91; N,10.48%.

20

PREPARATION 32

25 4-Methyl-1-{N-[3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl}-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester

The title compound (0.92g, 97%) was obtained from the title compound of Preparation 31 (0.93g, 1.2 mmol), using the procedure of Preparation 24, as a white foam. Rf 0.49 (SS 9). Found: C,56.45; H,7.18; N,9.89. $C_{38}H_{56}N_6O_9S$; H_2O ; 0.33 CH_2Cl_2 requires C,56.19; H,7.21; N,10.25%. m/e 773.4 (M+H)⁺.

-54-

PREPARATION 33

5 4-Methyl-1-[N-(3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid methyl ester dihydrochloride

The title compound (0.71g, 83%) was obtained from the title compound of Preparation 32 (0.92g, 1.2 mmol), using the procedure of Preparation 25, as a white powder. Rf 0.39 (SS 28). Found: C,48.11; H,6.88; N,11.44.

10 $C_{28}H_{40}N_6O_5S \cdot 2HCl$; 0.50 CH_2Cl_2 requires C,47.87; H,6.48; N,11.75%. m/e 573.4 (M+H)⁺.

PREPARATION 34

15 1-[N-t-Butoxycarbonyl-3-(3-pyridyl)-(S)-alanyl]-4(R)-methylpiperidine-2(R)-carboxylic acid ethyl ester

A stirred, ice-cooled suspension of N-t-butoxycarbonyl-3-(3-pyridyl)-(S)-alanine (Preparation 7; 2g, 7.5 mmol) in dichloromethane (20ml) was treated sequentially with 1-hydroxybenzotriazole (1.4g, 9.1 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2g, 10.4 mmol). After 20 10 minutes, the hydrochloride salt of the title compound of Preparation 14 (1.7g, 8.2 mmol) was added as a solution in dichloromethane (5ml), dropwise, followed by the dropwise addition of a solution of N-methylmorpholine (0.9g, 9 mmol) in dichloromethane (3ml). After 72 hours at room temperature, the solvent was evaporated under reduced pressure. The residue was dissolved in 25 ethyl acetate (50ml) and this solution was washed successively with saturated aqueous sodium bicarbonate solution and saturated brine, dried ($MgSO_4$), filtered and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel, using an elution gradient of ethyl acetate:hexane (10:90 to 100:0), to afford the title compound (2.1g, 67%) as a 30 hygroscopic foam. Rf 0.40 (SS 26). m/e 420.2 (M+H)⁺.

-55-

PREPARATION 35

5 1-[N-t-Butoxycarbonyl-3-(1-benzyl-3-pyridinium)-(S)-alanyl]-4(R)-
methylpiperidine-2(R)-carboxylic acid ethyl ester bromide

To a solution of the title compound of Preparation 34 (3.3g, 7.8 mmol) in dry ethanol (20ml) was added a solution of benzyl bromide (2.7g, 15.7 mmol) in dry ethanol (10ml), dropwise, over 5 minutes at room temperature. After 18 hours the ethanol was evaporated under reduced pressure. The residue was
10 dissolved in acetonitrile (30ml), then the solution extracted with hexane (3 x 10ml) and evaporated to dryness under reduced pressure. Solvent traces were removed azeotropically from the residue with dichloromethane to give the title compound (4.64g, 100%) which was used without further purification.

15

PREPARATION 36

1-[N-t-Butoxycarbonyl-3-(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-
4(R)-methylpiperidine-2(R)-carboxylic acid ethyl ester

Sodium borohydride (0.69g, 18 mmol) was added in two equal portions over 5 minutes to a stirred, ice-cooled solution of the title compound of
20 Preparation 35 (3.58g, 6 mmol) in ethanol (40ml). After 1 hour the solution was evaporated to dryness under reduced pressure. The residue was dissolved in dichloromethane (50ml) and the solution washed with saturated aqueous sodium bicarbonate solution (2 x 15ml) and saturated brine (15ml), dried (MgSO₄), filtered and evaporated under reduced pressure. The crude product
25 was purified by chromatography on silica gel, using an elution gradient of dichloromethane:hexane (75:25 to 100:0), followed by dichloromethane:methanol:0.880 aqueous ammonia (99:1:0.5 to 95:5:0.5), to furnish the title compound (3.18g, 80%) as a gum. R_f 0.80 (SS 9). m/e 514.4 (M+H)⁺.

-56-

PREPARATION 37

5 1-[3-(1-Benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-4(R)-
 methylpiperidine-2(R)-carboxylic acid ethyl ester dihydrochloride

 A stirred, ice-cooled solution of the title compound of Preparation 36 (3.1g, 6 mmol) in dichloromethane (40ml) was saturated with hydrogen chloride. After 1.5 hours the solvent and excess hydrogen chloride were removed under reduced pressure. Residual traces of hydrogen chloride were removed
10 azeotropically from the residue with dichloromethane to afford the title compound (3g, 100%) as a hygroscopic foam, which was used without further purification. R_f 0.42 (SS 9). m/e 414.3 (M+H)⁺.

PREPARATION 38

15 4(R)-Methyl-1-[N-(2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-
 sulphonyl]-3-(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-
 carboxylic acid ethyl ester

 A solution of N-ethyldiisopropylamine (1.6g, 12.4 mmol) in dichloromethane (5ml) was added dropwise over 5 minutes to a stirred ice-
20 cooled suspension of the title compound of Preparation 37 (1.5g, 3 mmol) and 2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride (Preparation 1; 1.1g, 3.3 mmol) in dichloromethane (15ml). After 18 hours at room temperature the solvent was evaporated under reduced pressure and the residue dissolved in ethyl acetate (50ml). This solution was washed with water
25 (2 x 10ml), saturated aqueous sodium bicarbonate solution (2 x 10ml) and saturated brine (10ml), dried (MgSO₄), filtered and evaporated under reduced pressure. The residue was purified by chromatography on silica gel, using an elution gradient of ethyl acetate:hexane:diethylamine (0:100:1 to 40:60:1), to yield the title compound (1g, 48%) as a pale yellow foam. R_f 0.70 (SS 9).
30 Found: C,58.95; H,5.83; N,7.47 C₃₅H₄₃F₃N₄O₆S requires C,59.64; H,6.15; N,7.95%. m/e 705.4 (M+H)⁺.

-57-

PREPARATION 39

5 4(R)-Methyl-1-[N-(2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-
sulphonyl)-3-(1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-carboxylic
acid ethyl ester

The title compound (0.76g, 84%) was obtained from the title compound of Preparation 38 (1g, 1.4 mmol), using the procedure of Preparation 21, as a white foam. Rf 0.25 (SS 9). Found: C,53.88; H,5.77; N,8.77. C₂₈H₃₇F₃N₄O₆S; 10 0.20 CH₂Cl₂ requires C,53.61; H,5.97; N,8.87%. m/e 615.4 (M+H)⁺.

PREPARATION 40

4(R)-Methyl-1-[N-[2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-
sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-

15 (S)-alanyl]piperidine-2(R)-carboxylic acid ethyl ester

The title compound (0.48g, 47%) was obtained from the title compound of Preparation 39 (0.74g, 1.2 mmol), using the procedure of Preparation 22, as a white foam and used without further purification. Rf 0.42 (SS 12). m/e 857.5 (M+H)⁺.

20

PREPARATION 41

4(R)-Methyl-1-[N-[1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-[1-(N,N'-
di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl]piperidine-

25 2(R)-carboxylic acid ethyl ester

The title compound (0.43g, 100%) was obtained from the title compound of Preparation 40 (0.47g, 0.5 mmol), using the procedure of Preparation 23, as a white foam. Rf 0.44 (SS 9). m/e 761.5 (M+H)⁺.

-58-

PREPARATION 42

5 4(R)-Methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-
[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-
alanyl]piperidine-2(R)-carboxylic acid ethyl ester

The title compound (0.34g, 82%) was obtained from the title compound of Preparation 41 (0.41g, 0.5 mmol), using the procedure of Preparation 24, as a white foam. Rf 0.57 (SS 9). Found: C,58.42; H,7.67; N,9.98. C₃₈H₅₈N₆O₉S requires C,58.89; H,7.54; N,10.84%. m/e 775.4 (M+H)⁺.
10

PREPARATION 43

15 4(R)-Methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-
(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-carboxylic
acid ethyl ester hydrochloride

The title compound (0.18g, 66%) was obtained from the title compound of Preparation 42 (0.33g, 0.4 mmol), using the procedure of Preparation 25, as a white powder. Rf 0.48 (SS 27). Found: C, 52.49; H,7.18; N,12.94. C₂₈H₄₂N₆O₅S; HCl; H₂O; 0.20 CH₂Cl₂ requires: C,52.41; H,7.08; N,13.00%. m/e
20 575.4 (M+H)⁺.

PREPARATION 44

4-Methyl-1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid methyl ester p-
toluenesulphonate

25 The title compound is obtainable via 4-methyl-1-[1-(R)-phenylethyl]-
1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid methyl ester by analogy with Preparation 16.

Alternatively, it may be obtained via 4-methyl-1-[1-(S)-phenylethyl]-1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid methyl ester hydrochloride which is a
30 by-product of Preparation 16, by subsequent processing as described in Preparation 16.

-59-

PREPARATION 454(R)-Methyl-2(S)-carboxylic acid methyl ester p-toluenesulphonate

- 5 A stirred solution of the title compound of Preparation 44 (2.0 g, 6.1 mmol) in methanol (20 ml) was hydrogenated over 10% palladium on charcoal at 414 kPa (60 p.s.i.) and room temperature for 20 hours, then the mixture filtered. The filtrate was evaporated under reduced pressure and the residue crystallised from 2-propanol to provide the title compound (1.2 g, 60%) as white
- 10 crystals. Rf 0.80 (SS 28). Found: C,54.51; H,7.28; N,3.94. $C_8H_{15}NO_2$; $C_7H_8O_3S$ requires C,54.69; H,7.04; N,4.25%.

PREPARATION 464(S)-Methyl-2(R)-carboxylic acid methyl ester p-toluenesulphonate

- 15 The title compound (2.0 g, 77%) was obtained from the title compound of Preparation 16, using the procedure of Preparation 45, as white crystals. Rf 0.80 (SS 28). Found: C,54.44; H,7.02; N,4.60. $C_8H_{15}NO_2$; $C_7H_8O_3S$ requires C,54.69; H,7.04; N,4.25%.

PREPARATION 474-Methyl-1-[N-(2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid methyl ester

- 20 The title compound (1.75 g, 82%) was obtained from the title compounds
- 25 of Preparation 13 (1.82 g, 3.1 mmol) and Preparation 44 (1.1 g, 3.4 mmol), using the procedure of Preparation 20, as a white foam. Rf 0.41 (SS 9). Found: C,57.42; H,5.20; N,7.87. $C_{34}H_{39}F_3N_4O_6S$; 0.33 CH_2Cl_2 requires C,57.50; H,5.57; N,7.81%. m/e 689.2 (M+H)⁺.

-60-

PREPARATION 48

5 4(R)-Methyl-1-[N-(2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-
3-(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(S)-carboxylic
acid methyl ester

The title compound (2.09 g, 95%) was obtained from the title compounds of Preparation 13 (1.88 g, 3.19 mmol) and Preparation 45 (1.15 g, 3.49 mmol), using the procedure of Preparation 20, as a white foam. Rf 0.52 (SS 26).

10 Found: C,58.58; H,5.81; N,7.77. C₃₄H₄₁F₃N₄O₆S; 0.075 CH₂Cl₂ requires C,58.71; H,5.95; N,8.04%. m/e 691.3 (M+H)⁺.

PREPARATION 49

15 4(S)-Methyl-1-[N-(2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-
(1-benzyl-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-carboxylic acid
methyl ester

The title compound (2.3 g, 92%) was obtained from the title compounds of Preparation 13 (2.13 g, 3.6 mmol) and Preparation 46 (1.3 g, 3.9 mmol), using the procedure of Preparation 20, as a white foam. Rf 0.50 (SS 26). Found:

20 C,58.80; H,5.89; N,7.98. C₃₄H₄₁F₃N₄O₆S requires C,59.12; H,5.98; N,8.11%. m/e 691.4 (M+H)⁺.

PREPARATION 50

25 4-Methyl-1-[N-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-
(1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(S)-
carboxylic acid methyl ester

The title compound (1.24 g, 83%) was obtained from the title compound of Preparation 47 (1.72 g, 2.5 mmol), using the procedure of Preparation 21, as a white foam. Rf 0.24 (SS 9). m/e 599.2 (M+H)⁺.

-61-

PREPARATION 51

5 4(R)-Methyl-1-[N-(2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-
3-(1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(S)-carboxylic acid methyl
ester hydrochloride

The title compound (1.47 g, 84%) was obtained from the title compound of Preparation 48 (2.0 g, 2.89 mmol), using the procedure of Preparation 21, as a pale yellow foam. Rf 0.30 (SS 9). Found: C,51.36; H,5.32; N,8.81.

10 $C_{27}H_{35}F_3N_4O_6S$; HCl requires C,50.90; H,5.70; N,8.79%. m/e 601.3 (M+H)⁺.

PREPARATION 52

15 4(S)-Methyl-1-[N-(2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-
(1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-carboxylic acid methyl
ester hydrochloride

The title compound (1.79 g, 89%) was obtained from the title compound of Preparation 49 (2.3 g, 3.3 mmol), using the procedure of Preparation 21, as a pale yellow foam. Rf 0.45 (SS 9). m/e 601.3 (M+H)⁺.

20

PREPARATION 53

4-Methyl-1-{N-[2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-[1-
(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl}-
1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid methyl ester

25 The title compound (1.47 g, 84%) was obtained from the title compound of Preparation 50 (1.24 g, 2.1 mmol), using the procedure of Preparation 22, as a white foam. Rf 0.25 (SS 12). Found: C,53.04; H,5.79; N,9.35.

$C_{38}H_{51}F_3N_6O_{10}S$; 0.33 CH_2Cl_2 requires C,52.96; H,5.99; N,9.66%. m/e 841.3 (M+H)⁺.

-62-

PREPARATION 54

4(R)-Methyl-1-{N-[2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-
5 [1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-
alanyl}piperidine-2(S)-carboxylic acid methyl ester

The title compound (1.52 g, 75%) was obtained from the title compound of Preparation 51 (1.45 g, 2.41 mmol), using the procedure of Preparation 22, as a white foam. Rf 0.60 (SS 29)

10

PREPARATION 55

4(S)-Methyl-1-{N-[2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-
[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-
alanyl}piperidine-2(R)-carboxylic acid methyl ester

15 The title compound (2.17 g, 88%) was obtained from the title compound of Preparation 52 (1.76 g, 2.9 mmol), using the procedure of Preparation 22, as a white foam. Rf 0.72 (SS 9).

PREPARATION 56

20 4-Methyl-1-{N-[1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl}-1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid methyl ester

The title compound (1.11 g, 86%) was obtained from the title compound of Preparation 53 (1.46 g, 1.74 mmol), using the procedure of Preparation 23, as
25 a white foam. Rf 0.43 (SS 9). m/e 745.3 (M+H)⁺.

PREPARATION 57

4(R)-Methyl-1-{N-[1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl}piperidine-2(S)-
30 carboxylic acid methyl ester

The title compound (850 mg, 64%) was obtained from the title compound of Preparation 54 (1.5 g, 1.78 mmol), using the procedure of Preparation 23, as a white foam. Rf 0.60 (SS 9). Found: C, 56.18; H, 7.09; N, 10.64. C₃₆H₅₄N₆O₉S; 0.30 CH₂Cl₂ requires C, 56.45; H, 7.13; N, 10.88%.

-63-

PREPARATION 58

5 4(S)-Methyl-1-{N-[1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl}piperidine-2(R)-carboxylic acid methyl ester

The title compound (1.17 g, 61%) was obtained from the title compound of Preparation 55 (2.17 g, 2.6 mmol), using the procedure of Preparation 23, as a white foam. Rf 0.45 (SS 9). m/e 747.5.

10

PREPARATION 59

4-Methyl-1-{N-[2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(S)-carboxylic acid methyl ester

15 The title compound (980 mg, 86%) was obtained from the title compound of Preparation 56 (1.11 g, 1.4 mmol), using the procedure of Preparation 24, as a white foam. Rf 0.59 (SS 25). Found: C,56.21; H,7.09; N,10.19. C₃₇H₅₄N₆O₉S; 0.50 CH₂Cl₂ requires C,56.19; H,6.92; N,10.48%.

20

PREPARATION 60

4(R)-Methyl-1-(N-[2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl}piperidine-2(S)-carboxylic acid methyl ester

25 The title compound (700 mg, 83%) was obtained from the title compound of Preparation 57 (830 mg, 1.11 mmol), using the procedure of Preparation 24, as a white foam. Rf 0.61 (SS 9). Found: C,58.38; H,7.50; N,10.51. C₃₇H₅₆N₆O₉S requires C,57.91; H,7.36; N,10.92. m/e 762 (M+H)⁺.

PREPARATION 61

30 4(S)-Methyl-1-{N-[2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl]-3-[1-(N,N'-di-t-butoxycarbonylamidino)-1,2,5,6-tetrahydro-3-pyridyl]-(S)-alanyl}piperidine-2(R)-carboxylic acid methyl ester

The title compound (1.0 g, 98%) was obtained from the title compound of Preparation 58 (1.0 g, 1.3 mmol), using the procedure of Preparation 24, as a

white foam. Rf 0.48 (SS 9). Found: C,58.23; H,7.55; N,10.64. C₃₇H₅₆N₆O₉S
5 requires C,57.91; H,7.36; N,10.92%.

PREPARATION 62

4-Methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-
amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(S)-
10 carboxylic acid methyl ester hydrochloride

The title compound (576 mg, 76%) was obtained from the title compound
of Preparation 59 (970 mg, 1.28 mmol), using the procedure of Preparation 25,
as a foam. Rf 0.41 (SS 27). Found: C,50.37; H,6.70; N,12.91. C₂₇H₃₈N₆O₅S;
HCl; 2H₂O; 0.25 CH₂Cl₂ requires C,50.16; H,6.72; N,12.88%. m/e 559.4
15 (M+H)⁺.

PREPARATION 63

4(R)-Methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-
amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(S)-carboxylic acid
20 methyl ester hydrochloride

The title compound (360 mg, 62%) was obtained from the title compound
of Preparation 60 (700 mg, 0.92 mmol), using the procedure of Preparation 25,
as a yellow foam. Rf 0.56 (SS 27). m/e 561.4 (M+H)⁺.

25

PREPARATION 64

4(S)-Methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-
amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-carboxylic acid
methyl ester dihydrochloride

The title compound (810 mg, 98%) was obtained from the title compound
30 of Preparation 61 (1.0 g, 1.3 mmol), using the procedure of Preparation 25, as
a white foam. Rf 0.48 (SS 27). Found: C,51.40; H,6.97; N,13.55.
C₂₇H₄₀N₆O₅S; 2HCl requires C,51.18; H,6.68; N,13.20%.

-65-

Biological activity

The following Table illustrates the in vitro inhibitory activities against
5 thrombin and trypsin for two of the compounds of the invention.

TABLE

EXAMPLE	Ki(M)	
	THROMBIN	TRYPSIN
5	1.9×10^{-9}	2.4×10^{-6}
6	9.9×10^{-9}	6.9×10^{-7}

10

Safety profile

Certain compounds of the invention have been tested at multiple doses of
up to 30 mg/kg i.v. in mouse and up to 100 mg/kg i.v. in rat without showing any
sign of adverse toxicity.


15

-66-

CLAIMS

1. A compound of formula (I):

5



or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity,

wherein Y is optionally monounsaturated C_3 - C_5 alkylene optionally substituted with C_1 - C_4 alkyl or methylene;

20 R^1 is H; C_1 - C_4 alkyl optionally substituted with C_1 - C_4 alkoxy, OH, NR^5R^6 , $CONR^5R^6$, C_3 - C_6 cycloalkyl or aryl; or C_3 - C_6 alkenyl;

R^2 is H; C_1 - C_4 alkyl optionally substituted with C_1 - C_4 alkoxy, OH, NR^5R^6 , $CONR^5R^6$, C_3 - C_6 cycloalkyl or aryl; or $CONR^5R^6$;

25 R^3 and R^4 are each independently selected from H; C_1 - C_4 alkyl optionally substituted with NR^5R^6 ; C_1 - C_4 alkoxy; halo; $CONR^5R^6$ and aryl;

aryl is phenyl optionally substituted with one, two or three substituents independently selected from C_1 - C_4 alkyl, C_1 - C_4 alkoxy, OH, halo and CF_3 ;


30 R^5 and R^6 are each independently selected from H and C_1 - C_4 alkyl;

and m and n are each independently 1, 2 or 3.

-67-


2. A compound according to claim 1 wherein the preferred stereoisomer is of formula (IA):

5



3. A compound according to claim 2 wherein Y is optionally monounsaturated C_4 alkylene substituted with methyl or ethyl; R^1 is C_1 - C_4 alkyl; R^2 is H; R^3 and R^4 are H; and m and n are each independently 1 or 2.

- 20 4. A compound according to claim 3 of formula (IB):



wherein --- represents an optional carbon-carbon single bond; R^1 and R^7 are methyl; m is 1 or 2; and n is 2.

-68-

5. A compound according to claim 4 wherein the compound of formula (IB) is selected from

5 4-methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid;

4-methyl-1-[N-(3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid; and

10

4(R)-methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-carboxylic acid;

and pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates of either entity.

15

6. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, according to any one of claims 1 to 5, together with a pharmaceutically acceptable diluent or carrier.

20 7. A compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, or a pharmaceutical composition containing any one of the foregoing, according to any of claims 1 to 6, for use as a medicament.

8. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, or a pharmaceutical composition containing any of the foregoing, according to any one of claims 1 to 6, for the manufacture of a medicament for the curative or prophylactic treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisation trauma,

25

30 application of lower limb plaster casts, or fractures of the lower limbs or pelvis; recurrent DVT; DVT during pregnancy when there is a previous history thereof; reocclusion following thrombolytic therapy; chronic arterial obstruction;


-69-

peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; disseminated

- 5 intravascular coagulation; coagulation in extra-corporeal circuits; occlusion of arterio-venous shunts and blood vessel grafts (including coronary artery by-pass grafts); restenosis and occlusion following angioplasty; neurodegenerative disorders; inflammatory disorders; or scarring.

9. A compound of formula (II):

10



- 20 wherein R^8 is C_1 - C_3 alkyl, and Y, R^1 , R^2 , R^3 , R^4 , m and n are as previously defined in claim 1.

10. A compound according to claim 9 wherein R^8 is methyl or ethyl.

11. A method of treating a mammal (including a human being) to cure or prevent deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisation trauma, application of lower limb plaster casts, or fractures of the lower limbs or pelvis; recurrent DVT; DVT during pregnancy when there is a previous history thereof; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; disseminated intravascular coagulation; coagulation in extra-corporeal circuits; occlusion of arterio-venous shunts and blood vessel grafts (including coronary artery by-pass grafts); restenosis and
- 25
- 30

-70-

occlusion following angioplasty; neurodegenerative disorders; inflammatory disorders; or scarring; which comprises treating said mammal with an effective
5 amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, or a pharmaceutical composition containing any of the foregoing, according to any one of claims 1 to 6.

10

15


20

25

-71-

12. A process for the preparation of a compound of formula (I):

5



15 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity,

wherein Y is optionally monounsaturated C₃-C₅ alkylene optionally substituted with C₁-C₄ alkyl or methylene;

20 R¹ is H; C₁-C₄ alkyl optionally substituted with C₁-C₄ alkoxy, OH, NR⁵R⁶, CONR⁵R⁶, C₃-C₆ cycloalkyl or aryl; or C₃-C₆ alkenyl;

R² is H; C₁-C₄ alkyl optionally substituted with C₁-C₄ alkoxy, OH, NR⁵R⁶, CONR⁵R⁶, C₃-C₆ cycloalkyl or aryl; or CONR⁵R⁶;

25 R³ and R⁴ are each independently selected from H; C₁-C₄ alkyl optionally substituted with NR⁵R⁶; C₁-C₄ alkoxy; halo; CONR⁵R⁶ and aryl;

aryl is phenyl optionally substituted with one, two or three substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halo and CF₃;

R⁵ and R⁶ are each independently selected from H and C₁-C₄ alkyl;


30 and m and n are each independently 1, 2 or 3;

which comprises acid- or base-catalysed hydrolysis of a compound of formula (II):

-72-

5

10



wherein R^8 is C_1 - C_3 alkyl, and Y , R^1 , R^2 , R^3 , R^4 , m and n are as previously defined in this claim;

15 followed by optional formation of a pharmaceutically acceptable salt of the required product or a pharmaceutically acceptable solvate of either entity.

13. A process according to claim 12 which is base-catalysed in aqueous medium, optionally in the presence of a cosolvent, at from about 0°C to about 100°C .

20 14. A process according to claim 13 wherein the base is an alkali metal hydroxide.


15. A process according to claim 14 wherein the base is sodium hydroxide and the reaction is conducted at from about 0°C to about room temperature.

25 16. A process according to any one of claims 12 to 15 wherein R^8 is methyl or ethyl.

17. A process according to any one of claims 12 to 16 wherein the preferred stereoisomer of a compound of formula (I) produced from the corresponding stereoisomer of a compound of formula (II) is of formula (IA):

30


5



18. A process according to claim 17 where Y is optionally monounsaturated
C₄ alkylene substituted with methyl or ethyl; R¹ is C₁-C₄ alkyl; R² is H; R³ and
15 R⁴ are H; and m and n are each independently 1 or 2.

19. A process according to claim 18 wherein the compound produced is of formula (IB):

20



25

wherein --- represents an optional carbon-carbon single bond; R¹ and R⁷ are methyl; m is 1 or 2; and n is 2.

30 20. A process according to claim 19 wherein the compound of formula (IB) produced is selected from

-74-

- 4-methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-
- 5 carboxylic acid;
- 4-methyl-1-[N-(3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid; and
- 10 4(R)-methyl-1-[N-(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-sulphonyl)-3-(1-amidino-1,2,5,6-tetrahydro-3-pyridyl)-(S)-alanyl]piperidine-2(R)-carboxylic acid;
- and pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates of either entity.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/01459

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D401/14 A61K31/47 A61K31/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 008 746 (MITSUBISHI CHEM IND ;OKAMOTO SHOSUKE (JP)) 19 March 1980 see the whole document	1-20
A	--- WO,A,92 08709 (PENTAPHARM AG) 29 May 1992 cited in the application see example 19	1-20
A	--- EP,A,0 623 595 (SQUIBB BRISTOL MYERS CO) 9 November 1994 see examples 13,14 -----	1-20

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

6 June 1996

Date of mailing of the international search report

14. 06. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

Int ional application No.

PCT/EP 96/01459

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 11 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Inte onal Application No

PCT/EP 96/01459

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0008746	19-03-80	AT-T- 1450	15-08-82
		AU-B- 520342	28-01-82
		AU-B- 5048679	06-03-80
		CA-A- 1135698	16-11-82
		JP-B- 1035000	21-07-89
		JP-C- 1556978	16-05-90
		JP-A- 55033499	08-03-80

WO-A-9208709	29-05-92	AU-B- 8868991	11-06-92
		CA-A- 2073776	16-05-92
		EP-A- 0511347	04-11-92
		JP-T- 5503300	03-06-93
		US-A- 5518735	21-05-96

EP-A-0623595	09-11-94	AU-B- 6183494	10-11-94
		CA-A- 2122397	04-11-94
		JP-A- 6329627	29-11-94
